<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma - Luvira, V - 2021 | Cochrane Library</title> <meta content="Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma - Luvira, V - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012814.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma - Luvira, V - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012814.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012814.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma" name="citation_title"/> <meta content="Vor Luvira" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="vor_110@yahoo.com" name="citation_author_email"/> <meta content="Egapong Satitkarnmanee" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Ake Pugkhem" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Chumnan Kietpeerakool" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Pisake Lumbiganon" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Porjai Pattanittum" name="citation_author"/> <meta content="Khon Kaen University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD012814.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/09/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012814.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012814.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012814.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Bile Duct Neoplasms [drug therapy, surgery]; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; *Cholangiocarcinoma [drug therapy, surgery]; Neoplasm Recurrence, Local; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012814.pub2&amp;doi=10.1002/14651858.CD012814.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="nnwvukoo";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012814\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012814\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012814.pub2",title:"Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma",firstPublishedDate:"Sep 13, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato-Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012814.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012814.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012814.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012814.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012814.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012814.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012814.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012814.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012814.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012814.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3392 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012814.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/appendices#CD012814-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/table_n/CD012814StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/table_n/CD012814StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#CD012814-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Vor Luvira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#CD012814-cr-0005">Egapong Satitkarnmanee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#CD012814-cr-0006">Ake Pugkhem</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#CD012814-cr-0007">Chumnan Kietpeerakool</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#CD012814-cr-0008">Pisake Lumbiganon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information#CD012814-cr-0009">Porjai Pattanittum</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information/en#CD012814-sec-0104">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 September 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012814.pub2">https://doi.org/10.1002/14651858.CD012814.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012814-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012814-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012814-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012814-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012814-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012814-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012814-abs-0001" lang="en"> <section id="CD012814-sec-0001"> <h3 class="title" id="CD012814-sec-0001">Background</h3> <p>Cholangiocarcinoma (cancer in the bile duct) is an aggressive tumour for which surgical resection is a mainstay of treatment. Despite complete resection, recurrences of the cancer are common and lead to poor prognosis in patients. Postoperative adjuvant chemotherapy given after surgical resection may reduce the risk of cancer recurrence by eradicating residual cancer and micrometastatic lesions. The benefits and harms of postoperative adjuvant chemotherapy versus placebo, no intervention, or other adjuvant chemotherapies are unclear. </p> </section> <section id="CD012814-sec-0002"> <h3 class="title" id="CD012814-sec-0002">Objectives</h3> <p>To assess the benefits and harms of postoperative adjuvant chemotherapy versus placebo, no intervention, or other adjuvant chemotherapies for people with cholangiocarcinoma after curative‐intent resection. </p> </section> <section id="CD012814-sec-0003"> <h3 class="title" id="CD012814-sec-0003">Search methods</h3> <p>We performed electronic searches in the Cochrane Hepato‐Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Trials, MEDLINE, Embase, LILACS, Science Citation Index Expanded, and Conference Proceedings Citation Index ‐ Science for trials that met the inclusion criteria up to 28 April 2021. </p> </section> <section id="CD012814-sec-0004"> <h3 class="title" id="CD012814-sec-0004">Selection criteria</h3> <p>Randomised clinical trials irrespective of blinding, publication status, or language comparing postoperative adjuvant chemotherapy versus placebo, no intervention, or a different postoperative adjuvant chemotherapy regimen for participants with curative‐intent resection for cholangiocarcinoma. </p> </section> <section id="CD012814-sec-0005"> <h3 class="title" id="CD012814-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods to develop and conduct the review. We conducted meta‐analyses and presented results, where feasible, using a random‐effects model and risk ratios (RR) with 95% confidence intervals (CI). We assessed risk of bias according to predefined domains suggested by Cochrane. We rated the certainty of evidence using the GRADE approach and presented outcome results in a summary of findings table. </p> </section> <section id="CD012814-sec-0006"> <h3 class="title" id="CD012814-sec-0006">Main results</h3> <p>We included five published randomised clinical trials. The trials included 931 adults (18 to 83 years old) who underwent curative‐intent resection for cholangiocarcinoma. Four trials compared postoperative adjuvant chemotherapy (mitomycin‐C and 5‐fluorouracil (5‐FU); gemcitabine; gemcitabine plus oxaliplatin; or capecitabine) versus no postoperative adjuvant chemotherapy (surgery alone) in 867 participants with cholangiocarcinoma only. A fifth trial compared postoperative adjuvant S‐1 (a novel oral fluoropyrimidine derivative) chemotherapy versus gemcitabine in 70 participants with intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma (64 participants), and gallbladder carcinoma (6 participants). We assessed all of the included trials at overall high risk of bias. One trial was conducted in France, three in Japan, and one in the United Kingdom. We could not perform all planned comparison analyses due to lack of data. Three trials used intention‐to‐treat analyses. Another trial used per‐protocol analysis. In the remaining trial one participant in the intervention group and one in the control group were lost to follow‐up. However, the outcomes of these two participants were not described. </p> <p><b>Postoperative adjuvant chemotherapy versus no postoperative adjuvant chemotherapy</b> </p> <p>We are very uncertain as to whether postoperative adjuvant chemotherapy has little to no effect on all‐cause mortality versus no postoperative adjuvant chemotherapy (RR 0.92, 95% CI 0.84 to 1.01; 4 trials, 867 participants, very low‐certainty evidence). We are very uncertain of the effect of postoperative adjuvant chemotherapy on serious adverse events (RR 17.82, 95% CI 2.43 to 130.82; 1 trial, 219 participants, very low‐certainty evidence). The trial indicated that postoperative adjuvant chemotherapy could increase serious adverse events, as 19/113 (20.5%) of participants developed an adverse event, compared to 1/106 (1.1%) of participants in the no‐postoperative adjuvant chemotherapy group. None of the included trials reported data on health‐related quality of life, cancer‐related mortality, time to recurrence of the tumour, and non‐serious adverse events in participants with only cholangiocarcinoma. </p> <p><b>Adjuvant S‐1 chemotherapy (fluoropyrimidine derivative) versus adjuvant gemcitabine‐based chemotherapy</b> </p> <p>The only available trial analysed all participants with intrahepatic, perihilar cholangiocarcinoma and gallbladder carcinoma together, with data on participants with cholangiocarcinoma not provided separately. The authors reported that one‐year overall mortality after adjuvant S‐1 therapy was lower than with adjuvant gemcitabine‐based therapy following major hepatectomy for biliary tract cancer. There were no differences in two‐year overall mortality. </p> <p>Funding: two trials received support from drug companies; one trial received funding from the Japan Society of Clinical Oncology; one trial received support from "Programme Hospitalier de Recherche Clinique (PHRC2009) and Ligue Nationale Contre le Cancer"; and one trial did not provide information on support or sponsorship. </p> <p>We identified six ongoing randomised clinical trials.</p> </section> <section id="CD012814-sec-0007"> <h3 class="title" id="CD012814-sec-0007">Authors' conclusions</h3> <p>Based on the very low‐certainty evidence found in four trials in people with curative‐intent resection for cholangiocarcinoma, we are very uncertain of the effects of postoperative adjuvant chemotherapy (mitomycin‐C and 5‐FU; gemcitabine; gemcitabine plus oxaliplatin; or capecitabine) versus no postoperative adjuvant chemotherapy on mortality. The effects of postoperative adjuvant chemotherapy compared with no postoperative adjuvant chemotherapy on serious adverse events are also very uncertain, but the result of the single trial showed 20% higher occurrences of haematologic adverse events. We assessed the certainty of the evidence as very low due to overall high risk of bias, and imprecision. Due to insufficient power of the only identified trial, the best postoperative adjuvant chemotherapy regimen in people with only cholangiocarcinoma could not be established. We also lack randomised clinical trials with outcome data on adjuvant S‐1 chemotherapy versus adjuvant gemcitabine‐based chemotherapy in people with cholangiocarcinoma alone. There is a need for further randomised clinical trials designed to be at low risk of bias and with adequate sample size exploring the best adjuvant chemotherapy treatment after surgery in people with cholangiocarcinoma. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012814-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012814-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012814-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012814-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012814-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012814-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012814-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012814-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012814-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012814-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012814-abs-0002" lang="en"> <h3>Postoperative chemotherapy for cholangiocarcinoma that can be surgically removed</h3> <p><b>Review question</b> </p> <p>What are the benefits and harms of postoperative adjuvant chemotherapy (drugs administered after surgery, aiming to kill any cancer left after the operation) versus no postoperative adjuvant chemotherapy or another type or form of chemotherapy in people who underwent resection for cholangiocarcinoma (cancer in the bile ducts) with intent to cure. </p> <p><b>Background</b> </p> <p>Cholangiocarcinoma is an aggressive tumour for which surgical resection is a mainstay of treatment. Bile ducts are the drainage 'pipes' that carry bile from the liver to the gallbladder, and from the gallbladder to the small intestine. Despite complete surgical removal (resection) of the cholangiocarcinoma, recurrences of tumour are common, leading to a poor prognosis for patients. It is thought that postoperative adjuvant chemotherapy (supplementary treatment after initial treatment) given after surgical resection may reduce the risk of cancer recurrence by eliminating residual cancer and micrometastatic lesions (microtumours that have spread from a cancer to distant areas of the body). The overall benefits and harms of this type of treatment are unclear. </p> <p><b>Study characteristics</b> </p> <p>We searched for published articles describing randomised clinical trials (a type of study where participants are randomly assigned to one of two or more treatment groups) to identify the role of postoperative adjuvant chemotherapy, and found five studies with a total of 931 participants. Four studies (867 participants) compared surgery and postoperative adjuvant chemotherapy (mitomycin‐C and 5‐fluorouracil (5‐FU); gemcitabine; gemcitabine plus oxaliplatin; or capecitabine) with surgery alone (no postoperative adjuvant chemotherapy). One study (70 participants; 64 with cholangiocarcinoma and 6 with gallbladder carcinoma) compared surgery and a new adjuvant oral chemotherapy (S‐1) (fluoropyrimidine derivative) versus surgery and adjuvant gemcitabine‐based chemotherapy. </p> <p>Funding: two trials received support from drug companies; one trial received funding from the Japan Society of Clinical Oncology; one trial received support from "Programme Hospitalier de Recherche Clinique (PHRC 2009) and Ligue Nationale Contre le Cancer"; and one trial did not provide information on support or sponsorship. </p> <p>We also identified six ongoing randomised clinical trials.</p> <p><b>Key results</b> </p> <p>We are very unsure as to whether postoperative adjuvant chemotherapy has any effect on death from any cause. Only one trial reported on adverse events. Whilst this trial indicated that postoperative adjuvant chemotherapy could increase serious adverse events, this result is very uncertain due to the lack of studies (i.e. only one found) and the low number of participants. No information was available on quality of life, death from cancer, time to tumour recurrence, and non‐serious adverse events. </p> <p><b>Conclusions</b> </p> <p>Due to poor study quality, an insufficient number of studies, and low number of participants, the effects of postoperative adjuvant chemotherapy versus no postoperative adjuvant chemotherapy on mortality and serious adverse events are very uncertain. More randomised clinical trials designed with better study methods and larger participant numbers are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012814-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012814-sec-0092"></div> <h3 class="title" id="CD012814-sec-0093">Implications for practice</h3> <section id="CD012814-sec-0093"> <p>Based on the very low‐certainty evidence found in four trials in people with curative‐intent resection for cholangiocarcinoma, we are very uncertain about the effects of postoperative adjuvant chemotherapy (mitomycin‐C and 5‐fluorouracil (5‐FU); gemcitabine; gemcitabine plus oxaliplatin; or capecitabine) versus no postoperative adjuvant chemotherapy on mortality. The effects of postoperative adjuvant chemotherapy on serious adverse events compared with no postoperative adjuvant chemotherapy are also very uncertain, but the result of the single included trial showed 20% higher occurrences of haematologic adverse events. We rated the certainty of the evidence as very low due to the overall trial risk of bias and imprecision, therefore these findings should be interpreted with caution, as a rating of very low certainty means that the true effect is likely to be substantially different from the estimate of effect. Due to insufficient power of the only identified trial, the best postoperative adjuvant chemotherapy regimen in people with only cholangiocarcinoma could not be established. </p> </section> <h3 class="title" id="CD012814-sec-0094">Implications for research</h3> <section id="CD012814-sec-0094"> <p>There is a need for high‐quality randomised clinical trials assessing the benefit of postoperative adjuvant treatment, including chemotherapy and chemo‐radiotherapy, for people with cholangiocarcinoma. It is very important that future trials focus on only people with cholangiocarcinoma. Moreover, there are at least two main subtypes of cholangiocarcinoma, that is papillary and tubular cholangiocarcinoma, which may need separate assessments. Future randomised clinical trials should plan to conduct subgroup analysis between these two subtypes. Moreover, future trials should include placebo as well as nocebo controls. Outcomes should include mortality, health‐related quality of life, and serious adverse events. The trials must be designed following the SPIRIT statement (Standard Protocol Items: Recommendations for Interventional Trials; <a href="http://www.spiritstatement.org" target="_blank">www.spiritstatement.org</a>), and their reporting should be according to the CONSORT statement (<a href="http://www.consort-statement.org" target="_blank">www.consort-statement.org</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012814-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012814-sec-0008"></div> <div class="table" id="CD012814-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Adjuvant chemotherapy compared with no chemotherapy for resectable cholangiocarcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adjuvant chemotherapy compared with no chemotherapy for resectable cholangiocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with resectable cholangiocarcinoma<br/><b>Setting:</b> secondary care <br/><b>Intervention:</b> adjuvant chemotherapy<br/><b>Comparison:</b> no chemotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no chemotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with adjuvant chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.84 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>867<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We used Trial Sequential Analysis to calculate diversity‐adjusted required information size (DARIS). DARIS was calculated based on event proportion in the control group of 59.3% (255/430), risk ratio of 10%, type I error of 2.5%, type II error of 10% (90% power), and heterogeneity correction based on model variance (trial diversity was 0%). The required information size was 3473 participants. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>593 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>546 per 1000<br/>(498 to 599) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> <p>Follow‐up:</p> <p>median: 79.4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 17.82<br/>(2.43 to 130.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>219<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events in the trial report were described as any serious adverse event, and not a specific toxicity. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000<br/>(23 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>There was no difference in time to definitive deterioration of global health‐related quality of life between those who received postoperative adjuvant GEMOX (gemcitabine and oxaliplatin) and those who did not. </p> <p>Participants receiving postoperative adjuvant capecitabine had worse social functioning compared with those who did not receive adjuvant chemotherapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both trials reported overall outcomes for all participants (cholangiocarcinoma and gallbladder carcinoma). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer‐related mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials reported this outcome for participants with cholangiocarcinoma alone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TIme to recurrence of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials reported this outcome for participants with cholangiocarcinoma alone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials reported this outcome for participants with cholangiocarcinoma alone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to methodological limitations (two levels): most trials had a high risk of performance and detection bias; and imprecision (one level); the optimal information size (OIS) of 3473 participants was not reached (see comment).<br/><sup>2</sup>Downgraded due to methodological limitations (two levels): the trial had a high risk of performance and detection bias; and imprecision (one level); the optimal information size (OIS) was not met (based on OIS using a conventional sample size calculation, the control group risk of 0.009, relative risk reduction (RRR) of 20%, α of 0.05, β of 0.20, the required sample size was 38,926 participants in each trial group). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012814-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Adjuvant S‐1 compared to gemcitabine for resectable cholangiocarcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adjuvant S‐1 compared to gemcitabine for resectable cholangiocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with resectable cholangiocarcinoma <br/><b>Setting:</b> secondary care <br/><b>Intervention:</b> adjuvant S‐1<br/><b>Comparison:</b> adjuvant gemcitabine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with adjuvant gemcitabine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with adjuvant S‐1</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality: 1‐year overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.38<br/>(0.15 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝ <br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64 of 70 participants in this trial had cholangiocarcinoma; 6 participants had gallbladder carcinoma. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000<br/>(56 to 357) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality: 2‐year overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/>(0.58 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝ <br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64 of 70 participants in this trial had cholangiocarcinoma; 6 participants had gallbladder carcinoma. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>743 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>602 per 1000<br/>(431 to 839) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝ <br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64 of 70 participants in this trial had cholangiocarcinoma; 6 participants had gallbladder carcinoma. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to methodological limitations (one level): the trial had a high risk of performance and detection bias; indirectness (one level): participants included people with other types of cancer; and imprecision (two levels): the sample size was not met, and there was a low number of events and a wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012814-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012814-sec-0009"></div> <section id="CD012814-sec-0010"> <h3 class="title" id="CD012814-sec-0010">Description of the condition</h3> <p>Cholangiocarcinoma is a malignant epithelial tumour arising in the bile duct (intrahepatic and extrahepatic bile ducts). Several conditions have been established as risk factors associated with cholangiocarcinoma including cirrhosis, hepatitis B, hepatitis C, chronic inflammation with liver injury secondary to the primary sclerosing cholangitis, and infection with <i>Opisthorchis viverrini</i> (South‐East Asian liver fluke) and <i>Clonorchis sinensis</i> (Chinese liver fluke) (<a href="./references#CD012814-bbs2-0030" title="BergquistA , vonSethE . Epidemiology of cholangiocarcinoma. Best Practice &amp; Research. Clinical Gastroenterology2015;29(2):221-32.">Bergquist 2015</a>; <a href="./references#CD012814-bbs2-0070" title="LuviraV , Kamsa-ArdS , Kamsa-ArdS , LuviraV , SrisukT , PugkhemA , et al. Association between repeated praziquantel treatment and papillary, and intrahepatic cholangiocarcinoma. Annals of Hepatology2018;17(5):802-9. [PMID: 30145559]">Luvira 2018</a>). The age‐standardised incidence rates of cholangiocarcinoma vary widely between the different geographical regions, largely due to variations in regional environmental risk factors, diets, and lifestyles (<a href="./references#CD012814-bbs2-0030" title="BergquistA , vonSethE . Epidemiology of cholangiocarcinoma. Best Practice &amp; Research. Clinical Gastroenterology2015;29(2):221-32.">Bergquist 2015</a>). Cholangiocarcinoma is relatively rare in Western countries, with age‐standardised incidence rates between 0.3 and 2.0 per 100,000 person‐years (<a href="./references#CD012814-bbs2-0031" title="BridgewaterJ , GallePR , KhanSA , LlovetJM , ParkJW , PatelT , et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Journal of Hepatology2014;60(6):1268-89. [PMID: 24681130]">Bridgewater 2014</a>). The age‐standardised incidence rate of cholangiocarcinoma in Asian countries ranges from 1 to 85 per 100,000 person‐years (<a href="./references#CD012814-bbs2-0031" title="BridgewaterJ , GallePR , KhanSA , LlovetJM , ParkJW , PatelT , et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Journal of Hepatology2014;60(6):1268-89. [PMID: 24681130]">Bridgewater 2014</a>). The highest age‐standardised incidence rate of cholangiocarcinoma is found in the northeast provinces of Thailand, where the liver fluke <i>O viverrini</i> is endemic (up to 113 per 100,000 person‐years in men and 50 per 100,000 person‐years in women) (<a href="./references#CD012814-bbs2-0082" title="ParkinDM , WhelanSL , FerlayJ , TeppoL , ThomasDB . Cancer incidence in five continents, vol. VIII, 2002. publications.iarc.fr/Book-And-Report-Series/Iarc-Scientific-Publications/Cancer-Incidence-In-Five-Continents-Volume-VIII-2002 (accessed 30 March 2021).">Parkin 2002</a>; <a href="./references#CD012814-bbs2-0094" title="SripaB , PairojkulC . Cholangiocarcinoma: lessons from Thailand. Current Opinion in Gastroenterology2008;24(3):349-56.">Sripa 2008</a>; <a href="./references#CD012814-bbs2-0030" title="BergquistA , vonSethE . Epidemiology of cholangiocarcinoma. Best Practice &amp; Research. Clinical Gastroenterology2015;29(2):221-32.">Bergquist 2015</a>; <a href="./references#CD012814-bbs2-0064" title="KhuntikeoN , LoilomeW , ThinkhamropB , ChamadolN , YongvanitP . A comprehensive public health conceptual framework and strategy to effectively combat cholangiocarcinoma in Thailand. PLOS Neglected Tropical Diseases2016;10(1):e0004293.">Khuntikeo 2016</a>). </p> <p>Cholangiocarcinoma is commonly classified based on anatomical location. The intrahepatic type is defined as a cholangiocarcinoma that arises in a bile duct proximal to a second‐degree bile duct. The perihilar type is located in the bile duct between a second‐degree bile duct and a junction of cystic duct and a common bile duct. The distal type is localised in the area between the insertion of a cystic duct and the ampulla of Vater (<a href="./references#CD012814-bbs2-0077" title="NakeebA , PittHA , SohnTA , ColemanJ , AbramsRA , PiantadosiS , et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Annals of Surgery1996;224(4):463-73.">Nakeeb 1996</a>). The American Joint Committee staging for Cancer (AJCC) tumour‐nodes metastasis (TNM) staging system for cholangiocarcinoma is displayed in <a href="./appendices#CD012814-sec-0100">Appendix 1</a> (<a href="./references#CD012814-bbs2-0078" title="National Comprehensive Cancer Network. Clinical practice guidelines in oncology: hepatobiliary cancers version 4, 2019. www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed 27 December 2019).">NCCN 2019</a>). </p> <p>Complete surgical resection remains the gold standard of treatment for cholangiocarcinoma (<a href="./references#CD012814-bbs2-0076" title="NaginoM , EbataT , YokoyamaY , IgamiT , SugawaraG , TakahashiY , et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Annals of Surgery2013;258(1):129-40. [PMID: 23059502]">Nagino 2013</a>; <a href="./references#CD012814-bbs2-0069" title="LuviraV , PugkhemA , BhudhisawasdiV , PairojkulC , SathitkarnmaneeE , LuviraV , et al. Long-term outcome of surgical resection for intraductal papillary neoplasm of the bile duct. Journal of Gastroenterology and Hepatology2017;32(2):527-33. [PMID: 27356284]">Luvira 2017a</a>). Malignancy‐positive surgical margins and regional lymph node metastasis negatively impact on the survival of people with cholangiocarcinoma who undergo curative‐intent resection (<a href="./references#CD012814-bbs2-0062" title="IsaT , KusanoT , ShimojiH , TakeshimaY , MutoY , FurukawaM . Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. American Journal of Surgery2001;181(6):507-11.">Isa 2001</a>; <a href="./references#CD012814-bbs2-0105" title="WeberSM , JarnaginWR , KlimstraD , DeMatteoRP , FongY , BlumgartLH . Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. Journal of the American College of Surgeons2001;193(4):384-91.">Weber 2001</a>; <a href="./references#CD012814-bbs2-0084" title="PattanathienP , KhuntikeoN , PromthetS , Kamsa-ArdS . Survival rate of extrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pacific Journal of Cancer Prevention2013;14(1):321-4.">Pattanathien 2013</a>; <a href="./references#CD012814-bbs2-0101" title="TitapunA , PugkhemA , LuviraV , SrisukT , SomintaraO , SaeseowOT , et al. Outcome of curative resection for perihilar cholangiocarcinoma in Northeast Thailand. World Journal of Gastrointestinal Oncology2015;7(12):503-12.">Titapun 2015</a>; <a href="./references#CD012814-bbs2-0069" title="LuviraV , PugkhemA , BhudhisawasdiV , PairojkulC , SathitkarnmaneeE , LuviraV , et al. Long-term outcome of surgical resection for intraductal papillary neoplasm of the bile duct. Journal of Gastroenterology and Hepatology2017;32(2):527-33. [PMID: 27356284]">Luvira 2017a</a>). Median survival of people who have malignancy‐negative resection margins range from 25 to 61 months, compared to 12 to 20 months in people with malignancy‐positive resection margins (<a href="./references#CD012814-bbs2-0062" title="IsaT , KusanoT , ShimojiH , TakeshimaY , MutoY , FurukawaM . Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. American Journal of Surgery2001;181(6):507-11.">Isa 2001</a>; <a href="./references#CD012814-bbs2-0084" title="PattanathienP , KhuntikeoN , PromthetS , Kamsa-ArdS . Survival rate of extrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pacific Journal of Cancer Prevention2013;14(1):321-4.">Pattanathien 2013</a>; <a href="./references#CD012814-bbs2-0101" title="TitapunA , PugkhemA , LuviraV , SrisukT , SomintaraO , SaeseowOT , et al. Outcome of curative resection for perihilar cholangiocarcinoma in Northeast Thailand. World Journal of Gastrointestinal Oncology2015;7(12):503-12.">Titapun 2015</a>). Median survivals were 10 to 12 months in people with a lymph node metastasis and 27 to 63 months for people without a lymph node metastasis (<a href="./references#CD012814-bbs2-0062" title="IsaT , KusanoT , ShimojiH , TakeshimaY , MutoY , FurukawaM . Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma. American Journal of Surgery2001;181(6):507-11.">Isa 2001</a>; <a href="./references#CD012814-bbs2-0084" title="PattanathienP , KhuntikeoN , PromthetS , Kamsa-ArdS . Survival rate of extrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. Asian Pacific Journal of Cancer Prevention2013;14(1):321-4.">Pattanathien 2013</a>; <a href="./references#CD012814-bbs2-0101" title="TitapunA , PugkhemA , LuviraV , SrisukT , SomintaraO , SaeseowOT , et al. Outcome of curative resection for perihilar cholangiocarcinoma in Northeast Thailand. World Journal of Gastrointestinal Oncology2015;7(12):503-12.">Titapun 2015</a>). </p> </section> <section id="CD012814-sec-0011"> <h3 class="title" id="CD012814-sec-0011">Description of the intervention</h3> <p>Chemotherapy is a drug therapy used to treat cancer, principally by inhibiting the growth and division of cancer cells and promoting cell death. Adjuvant (supplementary treatment after initial treatment) chemotherapy can be defined as an additional chemotherapy given after primary surgery or primary radiotherapy in an attempt to lessen the risk of the cancer returning by eradicating residual diseases, particularly micrometastatic lesions that are supposed to be outside the field of the primary treatment covered (<a href="./references#CD012814-bbs2-0035" title="CarterSK . Adjuvant chemotherapy of cancer. A review of its current status. Drugs1986;31(4):337-67.">Carter 1986</a>; <a href="./references#CD012814-bbs2-0086" title="PowellBL , CraigJB . Adjuvant chemotherapy of solid tumors. American Journal of the Medical Sciences1987;294(1):33-41.">Powell 1987</a>). Chemotherapy agents can be administered locally (e.g. topical application or intracavitary injection) or systemically (e.g. oral, intramuscular injection, or intravenous injection) administered. The choice of chemotherapy agents for each patient mainly depends on the type and stage of cancer, patient's performance status, and details of previous treatment received (<a href="./references#CD012814-bbs2-0035" title="CarterSK . Adjuvant chemotherapy of cancer. A review of its current status. Drugs1986;31(4):337-67.">Carter 1986</a>; <a href="./references#CD012814-bbs2-0086" title="PowellBL , CraigJB . Adjuvant chemotherapy of solid tumors. American Journal of the Medical Sciences1987;294(1):33-41.">Powell 1987</a>). Although the best chemotherapy for cholangiocarcinoma remains to be determined, 5‐fluorouracil (5‐FU) and gemcitabine, as a single chemotherapeutic agent or in combination with other drugs (e.g. cisplatin or oxaliplatin), have been proposed as active and well‐tolerated regimens (<a href="./references#CD012814-bbs2-0097" title="ThongprasertS . The role of chemotherapy in cholangiocarcinoma. Annals of Oncology2005;16(Suppl 2):ii93-6.">Thongprasert 2005</a>). </p> </section> <section id="CD012814-sec-0012"> <h3 class="title" id="CD012814-sec-0012">How the intervention might work</h3> <p>The mainstay of treatment of cholangiocarcinoma is surgical resection (<a href="./references#CD012814-bbs2-0088" title="RazumilavaN , GoresGJ . Cholangiocarcinoma. Lancet2014;383(9935):2168-79.">Razumilava 2014</a>; <a href="./references#CD012814-bbs2-0068" title="LuviraV , NilpraphaK , BhudhisawasdiV , PugkhemA , ChamadolN , Kamsa-ArdS . Cholangiocarcinoma patient outcome in northeastern Thailand: single-center prospective study. Asian Pacific Journal of Cancer Prevention2016;17(1):401-6.">Luvira 2016</a>). The operation for intrahepatic cholangiocarcinoma is resection of the involved hemi‐liver. For perihilar cholangiocarcinoma, additional bile duct resection, complete caudate lobe resection, and hepato‐duodenal lymph node dissection are required. Pancreaticoduodenectomy is the operation of choice for people with distal cholangiocarcinoma (<a href="./references#CD012814-bbs2-0088" title="RazumilavaN , GoresGJ . Cholangiocarcinoma. Lancet2014;383(9935):2168-79.">Razumilava 2014</a>). Although complete resection offers the best chance of cure for people with cholangiocarcinoma, recurrence can be high, ranging from 46% to 61% (<a href="./references#CD012814-bbs2-0105" title="WeberSM , JarnaginWR , KlimstraD , DeMatteoRP , FongY , BlumgartLH . Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. Journal of the American College of Surgeons2001;193(4):384-91.">Weber 2001</a>; <a href="./references#CD012814-bbs2-0110" title="YamamotoM , TakasakiK , OtsuboT , KatsuragawaH , KatagiriS . Recurrence after surgical resection of intrahepatic cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Surgery2001;8(2):154–7.">Yamamoto 2001</a>; <a href="./references#CD012814-bbs2-0060" title="HyderO , HatzarasI , SotiropoulosGC , PaulA , AlexandrescuS , MarquesH , et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery2013;153(6):811-8.">Hyder 2013</a>). Cholangiocarcinoma can recur locally in the remaining liver or systemically in the distant organs. It is generally accepted that the recurrence of cancers arises not only because of inadequacy of surgical resection, but it is also secondary to pre‐existing microscopic cancer that spread systematically (<a href="./references#CD012814-bbs2-0027" title="Al UstwaniO , IancuD , YacoubR , IyerR . Detection of circulating tumor cells in cancers of biliary origin. Journal of Gastrointestinal Oncology2012;3(2):97-104.">Al Ustwani 2012</a>). This concept motivates the attempt of postoperative adjuvant chemotherapy to supplement surgical resection in order to eradicate microscopic disease following resection of clinically detectable lesions, and in order to achieve long‐term prevention of cancer growth of cholangiocarcinoma. </p> <p>A number of Cochrane Reviews have addressed the benefits of adjuvant chemotherapy given after primary surgery in lengthening survival in a variety of cancers (<a href="./references#CD012814-bbs2-0040" title="FigueredoA , CoombesME , MukherjeeS . Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database of Systematic Reviews2008, Issue 3. Art. No: CD005390. [DOI: 10.1002/14651858.CD005390.pub2]">Figueredo 2008</a>; <a href="./references#CD012814-bbs2-0085" title="PetersenSH , HarlingH , KirkebyLT , Wille-JørgensenP , MocellinS . Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD004078. [DOI: 10.1002/14651858.CD004078.pub2]">Petersen 2012</a>; <a href="./references#CD012814-bbs2-0034" title="BurdettS , PignonJP , TierneyJ , TribodetH , StewartL , Le PechouxC , et al, the Non-Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD011430. [DOI: 10.1002/14651858.CD011430]">Burdett 2015</a>; <a href="./references#CD012814-bbs2-0066" title="LawrieTA , Winter-RoachBA , HeusP , KitchenerHC . Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews2015, Issue 12. Art. No: CD004706. [DOI: 10.1002/14651858.CD004706.pub5]">Lawrie 2015</a>). In people with completely resected stage II colon cancer, adjuvant chemotherapy reduced the risk of cancer recurrence by approximately 17% compared with the control group who underwent surgery alone (risk ratio (RR) for disease‐free survival 0.83, 95% confidence interval (CI) 0.75 to 0.92; certainty of evidence: not available) (<a href="./references#CD012814-bbs2-0040" title="FigueredoA , CoombesME , MukherjeeS . Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database of Systematic Reviews2008, Issue 3. Art. No: CD005390. [DOI: 10.1002/14651858.CD005390.pub2]">Figueredo 2008</a>). In people with rectal cancer undergoing curative‐intent surgery, adjuvant chemotherapy reduced the risk of death by 17% (hazard ratio (HR) 0.83, 95% CI 0.76 to 0.91; certainty of evidence: not available) and disease recurrence by 25% (HR 0.75, 95% CI 0.68 to 0.83; certainty of evidence: not available) amongst people undergoing postoperative adjuvant chemotherapy compared with people undergoing observation (<a href="./references#CD012814-bbs2-0085" title="PetersenSH , HarlingH , KirkebyLT , Wille-JørgensenP , MocellinS . Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database of Systematic Reviews2012, Issue 3. Art. No: CD004078. [DOI: 10.1002/14651858.CD004078.pub2]">Petersen 2012</a>). When compared with the control group, postoperative adjuvant chemotherapy given to women with early‐stage ovarian cancer reduced the 10‐year risk of death (RR 0.76, 95% CI 0.62 to 0.94; certainty of evidence: high) and the risk of disease progression (RR 0.72, 95% CI 0.60 to 0.87; certainty of evidence: high) (<a href="./references#CD012814-bbs2-0066" title="LawrieTA , Winter-RoachBA , HeusP , KitchenerHC . Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews2015, Issue 12. Art. No: CD004706. [DOI: 10.1002/14651858.CD004706.pub5]">Lawrie 2015</a>). Additionally, compared with surgery alone, adjuvant chemotherapy in people with resected early‐stage non‐small cell lung cancer reduced the risk of death by approximately 14% (HR 0.86, 95% CI 0.81 to 0.92; certainty of evidence: not available) (<a href="./references#CD012814-bbs2-0034" title="BurdettS , PignonJP , TierneyJ , TribodetH , StewartL , Le PechouxC , et al, the Non-Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database of Systematic Reviews2015, Issue 3. Art. No: CD011430. [DOI: 10.1002/14651858.CD011430]">Burdett 2015</a>). There is evidence suggesting benefit of chemotherapy in advanced biliary tract cancer (<a href="./references#CD012814-bbs2-0042" title="GlimeliusB , HoffmanK , SjödénPO , JacobssonG , SellströmH , EnanderLK , et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals of Oncology1996;7(6):593-600. [PMID: 8879373]">Glimelius 1996</a>; <a href="./references#CD012814-bbs2-0072" title="MarinJJ , PreteMG , LamarcaA , TavolariS , Landa-MagdalenaA , BrandiG , et al. Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer2020;123(7):1047-59. [PMID: 32694694]">Marin 2020</a>). Various retrospective studies investigated the efficacy of numerous chemotherapeutic agents in the adjuvant setting that previously had demonstrated activity in locally advanced and metastatic biliary tract cancer, and found that adjuvant chemotherapy was associated with longer survival (<a href="./references#CD012814-bbs2-0059" title="HorganAM , AmirE , WalterT , KnoxJJ . Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology2012;30(16):1934-40. [PMID: 22529261]">Horgan 2012</a>; <a href="./references#CD012814-bbs2-0029" title="BelkouzA , WilminkJW , Haj MohammadN , HagendoornJ , deVos-GeelenJ , DejongCH , et al. Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. Critical Reviews in Oncology/Hematology2020;151:102975. [PMID: 32464483]">Belkouz 2020</a>). </p> </section> <section id="CD012814-sec-0013"> <h3 class="title" id="CD012814-sec-0013">Why it is important to do this review</h3> <p>Although various novel surgical techniques for treating cholangiocarcinoma have been developed, prognosis of patients after resection remains poor. Interventions for improving treatment outcomes amongst people with cholangiocarcinoma operated for cure are therefore needed. The high tendency for cholangiocarcinomas to recur provides a rationale for adjuvant therapy after definitive surgery (<a href="./references#CD012814-bbs2-0111" title="YangH , ZhouJ , WeiX , WangF , ZhaoH , LiE . Survival outcomes and prognostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: adjuvant therapy is a favorable prognostic factor. Molecular and Clinical Oncology2014;2(6):1069-75.">Yang 2014</a>). Postoperative adjuvant chemotherapy appears to be a promising adjuvant treatment for people with cholangiocarcinoma. However, to our knowledge, there has been no systematic review or meta‐analysis evaluating the effectiveness of postoperative adjuvant chemotherapy following surgical resection of cholangiocarcinoma. We therefore conducted this Cochrane Review to evaluate the effectiveness and safety of postoperative adjuvant chemotherapy for people with cholangiocarcinoma undergoing curative‐intent surgery. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012814-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012814-sec-0014"></div> <p>To assess the benefits and harms of postoperative adjuvant chemotherapy versus placebo, no intervention, or other adjuvant chemotherapies for people with cholangiocarcinoma after curative‐intent resection. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012814-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012814-sec-0015"></div> <section id="CD012814-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012814-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised clinical trials irrespective of blinding, publication status, or language. We planned to extract and present narrative data on harm from quasi‐randomised and observational studies if these were retrieved with the search results, as adverse events are rarely reported in randomised clinical trials (<a href="./references#CD012814-bbs2-0096" title="StorebøOJ , PedersenN , RamstadE , KielsholmML , NielsenSS , KroghHB , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews2018, Issue 5. Art. No: CD012069. [DOI: 10.1002/14651858.CD012069.pub2]">Storebø 2018</a>). We planned to include unpublished trials only if trial data and methodological descriptions were provided in written form or obtained through direct contact with study authors. We did not expect to find trials with cross‐over or cohort designs because of the nature of the interventions. </p> </section> <section id="CD012814-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults (aged 18 years or older) of any sex who underwent curative‐intent resection for cholangiocarcinoma and received any type of postoperative adjuvant chemotherapy compared with people with the same condition, but receiving placebo, no postoperative adjuvant chemotherapy, or other adjuvant chemotherapies. </p> <p>We only included trials with participants whose diagnosis of cholangiocarcinoma was established by pathological examination of surgical specimens. If studies included many types of biliary tract cancer (cholangiocarcinoma, gallbladder and ampulla of Vater carcinoma), we contacted authors to obtain disaggregated information specific for cholangiocarcinoma participants (See <a href="./references#CD012814-sec-0113" title="">Characteristics of included studies</a> for details). We intended to include people receiving any type of neoadjuvant treatment prior to operation, who were subsequently randomised to postoperative adjuvant chemotherapy, if the co‐interventions were equally applied in the trial groups. </p> </section> <section id="CD012814-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD012814-sec-0020"> <h5 class="title">Experimental interventions</h5> <p>All regimens of postoperative adjuvant chemotherapy (intravenous infusion, intravenous bolus, intraportal infusion, and oral administration of a single regimen or a combination of chemotherapy regimens). </p> </section> <section id="CD012814-sec-0021"> <h5 class="title">Control group</h5> <p>No postoperative adjuvant chemotherapy (surgery alone), placebo, or a different regimen or form of chemotherapy. </p> </section> </section> <section id="CD012814-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD012814-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012814-list-0001"> <li> <p>All‐cause mortality.</p> </li> <li> <p>Serious adverse events. We used the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice's definition of a serious adverse event (<a href="./references#CD012814-bbs2-0061" title="International Conference on Harmonisation Expert Working Group. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice CFR &amp; ICH Guidelines. Vol. 1. Philadelphia: Barnett International/PAREXEL, 1997.">ICH‐GCP 1997</a>), i.e. any untoward medical occurrence that results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. We considered all other adverse events as non‐serious (see below). </p> </li> <li> <p>Health‐related quality of life (as reported by the participants and as assessed by standard grading systems measured on a valid scale (e.g. Functional Assessment of Cancer Therapy‐Hepatobiliary cancers) (<a href="./references#CD012814-bbs2-0039" title="FACIT Group. Functional assessment of cancer therapy - Hepatobiliary cancers (FACT-Hep). www.facit.org/measures/FACT-Hep (accessed 8 September 2021).">FACT‐Hep 2015</a>). </p> </li> </ul> </p> </section> <section id="CD012814-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012814-list-0002"> <li> <p>Cancer‐related mortality (death from cancer).</p> </li> <li> <p>Time to recurrence of the tumour.</p> </li> <li> <p>Non‐serious adverse events.</p> </li> </ul> </p> <p>We performed our primary analyses using the outcome data at the last follow‐up.</p> </section> </section> </section> <section id="CD012814-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012814-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register (maintained and searched internally by the Cochrane Hepato‐Biliary Group Information Specialist via the Cochrane Register of Studies Web; 28 April 2021), the Cochrane Central Register of Controlled Trials (2021, Issue 4; date of search 28 April 2021) in the Cochrane Library, MEDLINE Ovid (1946 to 28 April 2021), Embase Ovid (1974 to 28 April 2021), LILACS (Latin American and Caribbean Health Science Information database) (BIREME; 1982 to 28 April 2021), Science Citation Index Expanded (Web of Science; 1900 to 28 April 2021), and Conference Proceedings Citation Index ‐ Science (Web of Science; 1990 to 28 April 2021). The search strategies for identification of relevant studies for the review are provided in <a href="./appendices#CD012814-sec-0101">Appendix 2</a>. </p> <p>There was no language restriction for this systematic review.</p> </section> <section id="CD012814-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of articles retrieved by the search and contacted trial authors to obtain additional data where necessary. </p> <p>We searched the online trial registries ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>), European Medicines Agency (EMA) (<a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema/</a>), World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>), Google Scholar (<a href="http://scholar.google.com" target="_blank">scholar.google.com</a>), US Food and Drug Administration (FDA) (<a href="http://www.fda.gov" target="_blank">www.fda.gov</a>), and pharmaceutical company sources for ongoing or unpublished trials (date of search 11 May 2021). </p> <p>We contacted the Cholangiocarcinoma Foundation of Thailand (<a href="https://cloud.cascap.in.th" target="_blank">cloud.cascap.in.th</a>) on 3 May 2021, and obtained one ongoing trial. </p> <p>We also contacted the Cholangiocarcinoma Foundation (<a href="https://cholangiocarcinoma.org/" target="_blank">cholangiocarcinoma.org/</a>) and the Alan Morement Memorial Fund (<a href="https://ammf.org.uk/" target="_blank">ammf.org.uk/</a>) on 21 May 2021 and 3 June 2021, but obtained no additional trials. </p> </section> </section> <section id="CD012814-sec-0028"> <h3 class="title" id="CD012814-sec-0028">Data collection and analysis</h3> <p>We performed the review following the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012814-bbs2-0058" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We performed the analyses using Review Manager 5 (<a href="./references#CD012814-bbs2-0089" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>), and performed Trial Sequential Analysis (TSA) to evaluate imprecision for our primary outcomes (<a href="./references#CD012814-bbs2-0100" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017. Available from ctu.dk/tsa/learn-more.">Thorlund 2017</a>; <a href="./references#CD012814-bbs2-0102" title="Copenhagen Trial UnitTSA - Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2017. Available at ctu.dk/tsa/downloads/.">TSA 2017</a>; <a href="./references#CD012814-bbs2-0108" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). We contacted the authors of two trials for information specific to participants with cholangiocarcinoma alone. The authors of one trial provided the requested information (<a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>), whilst the authors of the other trial did not reply to our requests (<a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>). </p> <section id="CD012814-sec-0029"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by the electronic searches to a reference management database (<a href="./references#CD012814-bbs2-0038" title="EndNote Version X7. Thomas Reuters. New York (NY): Thomas Reuters, 2015.">EndNote</a>). We removed duplicate publications, and then transferred the remaining results to <a href="./references#CD012814-bbs2-0036" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, 2020. Available at covidence.org.">Covidence</a>. After excluding studies that clearly did not match the review criteria, we obtained the full texts of potentially relevant references for detailed reviewing. Two review authors (VL and ES) independently assessed the eligibility of the retrieved publications. Any disagreements were resolved through discussion or by consulting a third review author (AP or CK) when necessary. We identified no multiple publications of the included trials nor publications with follow‐up trial data. We used the details of the selection process in <a href="./references#CD012814-bbs2-0036" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, 2020. Available at covidence.org.">Covidence</a> to create a PRISMA flow diagram (<a href="./references#CD012814-bbs2-0067" title="LiberatiA , AltmanD , TetzlaffJ , MulrowC , GotzscheP , IoannidisJ , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ (Clinical Research Ed.)2009;339:b2700.">Liberati 2009</a>). </p> </section> <section id="CD012814-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (VL and ES) independently extracted study characteristics and outcome data from the included trials using <a href="./references#CD012814-bbs2-0036" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, 2020. Available at covidence.org.">Covidence</a>. We noted in the <a href="./references#CD012814-sec-0113" title="">Characteristics of included studies</a> table if outcome data were not reported in a useable way. Any disagreements were resolved by consensus or by involving a third review author (AP or CK). One review author (PP) transferred data into Review Manager 5 (<a href="./references#CD012814-bbs2-0089" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). Another review author (PL) checked the study characteristics for accuracy against the trial report. </p> <p>We extracted the following data from the included trials: author, year of publication, and journal citation (including language); country; setting; inclusion and exclusion criteria; study methodology; study population and characteristics; total number enrolled, participant characteristics, age, comorbidities, other baseline characteristics, stage of cholangiocarcinoma, tumour size in largest diameter, histopathological type, status of surgical margin and lymph nodes, volume of residual lesion; intervention details, regimens of adjuvant chemotherapy, dose of adjuvant chemotherapy; comparison details; risk of bias in study (see below); duration of follow‐up; outcomes; results; trial funding/sponsorship, notable conflicts of interest of trial authors. </p> <p>We planned the following.</p> <p> <ul id="CD012814-list-0003"> <li> <p>For time‐to‐event data (e.g. time to recurrence of the tumour), we would extract the log of the hazard ratio (log(HR)) and its standard error from the trial reports. If these were not reported, we would attempt to estimate the log (HR) and its standard error using the methods of <a href="./references#CD012814-bbs2-0083" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>. </p> </li> <li> <p>For dichotomous outcomes (e.g. all‐cause mortality and adverse events), we extracted the number of people in each intervention group who experienced the outcome of interest and the number of people assessed at the end of follow‐up, to estimate a risk ratio (RR). </p> </li> <li> <p>For continuous outcomes (e.g. health‐related quality of life), we planned to extract the final value and standard deviation of the outcome of interest and the number of people assessed at the end of follow‐up in each intervention group, to estimate the mean difference between the treatment arms. There were no continuous data to be extracted. </p> </li> </ul> </p> <p>We calculated 95% confidence intervals (CI) for each estimate.</p> <p>Where possible, all data extracted were to be those relevant to the conductance of intention‐to‐treat analysis, in which participants were analysed in the groups to which they had been assigned. </p> </section> <section id="CD012814-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (VL and ES) independently assessed the risk of bias of each included trial according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012814-bbs2-0058" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), and methodological studies (<a href="./references#CD012814-bbs2-0093" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408-12.">Schulz 1995</a>; <a href="./references#CD012814-bbs2-0074" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet1998;352(9128):609-13.">Moher 1998</a>; <a href="./references#CD012814-bbs2-0065" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine2001;135(11):982-9.">Kjaergard 2001</a>; <a href="./references#CD012814-bbs2-0109" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanGD , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.)2008;336:601-5.">Wood 2008</a>; <a href="./references#CD012814-bbs2-0090" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment2012;16(35):1-82.">Savović 2012a</a>; <a href="./references#CD012814-bbs2-0091" title="SavovićJ , JonesHE , AltmanDG , HarrisRJ , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429-38.">Savović 2012b</a>; <a href="./references#CD012814-bbs2-0092" title="SavovićJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJP , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: The ROBES Meta-Epidemiologic Study. American Journal of Epidemiology2018;187(5):1113-22.">Savović 2018</a>). We used the following definitions in our risk of bias assessment. </p> <section id="CD012814-sec-0032"> <h5 class="title">Allocation sequence generation</h5> <p> <ul id="CD012814-list-0004"> <li> <p>Low risk of bias: the study performed sequence generation using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the study. </p> </li> <li> <p>Unclear risk of bias: the study authors did not specify the method of sequence generation.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random.</p> </li> </ul> </p> </section> <section id="CD012814-sec-0033"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD012814-list-0005"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. A central and independent randomisation unit controlled allocation. The investigators were unaware of the allocation sequence (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Unclear risk of bias: the study authors did not describe the method used to conceal the allocation, so the intervention allocations may have been foreseen before, or during, enrolment. </p> </li> <li> <p>High risk of bias: it is likely that the investigators who assigned the participants knew the allocation sequence. </p> </li> </ul> </p> </section> <section id="CD012814-sec-0034"> <h5 class="title">Blinding of participants and personnel</h5> <p> <ul id="CD012814-list-0006"> <li> <p>Low risk of bias: any of the following: no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; or blinding of participants and key study personnel ensured, and it is unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit a judgement of 'low risk' or 'high risk', or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: any of the following: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; or blinding of key study participants and personnel attempted, but it is likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD012814-sec-0035"> <h5 class="title">Blinded outcome assessment</h5> <p> <ul id="CD012814-list-0007"> <li> <p>Low risk of bias: any of the following: no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; or blinding of outcome assessment ensured, and it is unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit a judgement of 'low risk' or 'high risk', or the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: any of the following: no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; or blinding of outcome assessment, but it is likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD012814-sec-0036"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD012814-list-0008"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD012814-sec-0037"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD012814-list-0009"> <li> <p>Low risk of bias: the trial reported the following predefined outcomes: all‐cause mortality, serious adverse events, and time to recurrence of the tumour. If the original trial protocol is available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g. ClinicalTrials.gov), the outcomes sought should be those enumerated in the original protocol if the trial protocol was registered before or at the time the trial was begun. If the trial protocol was registered after the trial was begun, we will not consider those outcomes to be reliable. </p> </li> <li> <p>Unclear risk of bias: the study authors did not report all predefined outcomes fully, or it is unclear whether the study authors recorded data on these outcomes or not. </p> </li> <li> <p>High risk of bias: the study authors did not report one or more predefined outcomes.</p> </li> </ul> </p> </section> <section id="CD012814-sec-0038"> <h5 class="title">Other bias</h5> <p> <ul id="CD012814-list-0010"> <li> <p>Low risk of bias: the trial appeared to be free of other factors that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not have been free of other factors that could have put it at risk of bias. </p> </li> <li> <p>High risk of bias: there were other factors in the trial that could put it at risk of bias. </p> </li> </ul> </p> <p>We judged a trial to be at an overall low risk of bias if all of the above domains were assessed at low risk of bias. We judged a trial to be at an overall high risk of bias if one or more of the above domains were assessed at unclear or high risk of bias. </p> <p>Any differences in opinion were resolved through discussion; in the case of unsettled disagreements, a third review author adjudicated. </p> </section> </section> <section id="CD012814-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment.</p> <p> <ul id="CD012814-list-0011"> <li> <p>For dichotomous outcomes, we analysed data based on the number of events and the number of people assessed in the experimental and comparison groups. We used these to calculate the RR and 95% CI and Trial Sequential Analysis‐adjusted CI. </p> </li> <li> <p>For continuous outcomes, we planned to analyse data based on the mean, standard deviation, and number of people assessed for both the experimental and comparison groups to calculate the mean difference between treatment groups with a 95% CI and Trial Sequential Analysis‐adjusted CI. We planned that if the mean difference was reported without individual group data, we would use this mean difference to report the study results. If more than one study measured the same outcome using different tools, we would calculate the standardised mean difference and 95% CI using the inverse‐variance method. </p> </li> </ul> </p> </section> <section id="CD012814-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the trial and trial participants randomised to each intervention group. If a trial had two or more experimental intervention groups that shared a common control group, we would divide the control group into the respective number of experimental intervention groups of interest to us if they were part of the same comparison. We did not identify any trials with multiple intervention arms. We did not expect to find trials with a cross‐over design or cluster‐randomised trials. </p> </section> <section id="CD012814-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study authors to obtain missing data. We did not impute missing outcome data and only analysed the data available in the trial reports. </p> </section> <section id="CD012814-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess heterogeneity amongst the included trials using visual inspection of the forest plots to consider both the direction and magnitude of effects and the degree of overlap between confidence interval. We also assessed statistical heterogeneity in each meta‐analysis using the I<sup>2</sup> statistic and Chi<sup>2</sup> test (<a href="./references#CD012814-bbs2-0057" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.)2003;327(7414):557-60.">Higgins 2003</a>). We regarded heterogeneity as substantial if the I<sup>2</sup> statistic value was greater than 50%, or there was a low P value (less than 0.10) in the Chi<sup>2</sup> test for heterogeneity (<a href="./references#CD012814-bbs2-0037" title="DeeksJ , AltmanD , BradburnM . Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London (UK): BMJ Publishing Group, 2001:285-312.">Deeks 2001</a>; <a href="./references#CD012814-bbs2-0058" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). If there was substantial statistical heterogeneity, we would carry out subgroup analyses to assess differences between the included trials in terms of clinical and methodological characteristics as described in <a href="#CD012814-sec-0046">Subgroup analysis and investigation of heterogeneity</a>. </p> </section> <section id="CD012814-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>Given the small number of included trials, we did not examine funnel plots corresponding to meta‐analysis of the primary outcome all‐cause mortality to assess the potential for small‐study effects such as publication bias. In future updates, if 10 or more trials are identified, we will assess funnel plot asymmetry visually, and if asymmetry of funnel plots is identified, we will perform exploratory analyses to investigate it (see <a href="#CD012814-sec-0108">Differences between protocol and review</a>) (<a href="./references#CD012814-bbs2-0095" title="SterneJ , SuttonA , IoannidisJ , TerrinN , JonesD , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ (Clinical Research Ed.)2011;343:d4002.">Sterne 2011</a>). </p> </section> <section id="CD012814-sec-0044"> <h4 class="title">Data synthesis</h4> <section id="CD012814-sec-0045"> <h5 class="title">Meta‐analysis</h5> <p>See <a href="#CD012814-sec-0108">Differences between protocol and review</a>. </p> <p>We performed the analysis using Review Manager 5 (<a href="./references#CD012814-bbs2-0089" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). Where feasible, the results were meta‐analysed. We planned to perform meta‐analysis using random‐effects and fixed‐effect models in all meta‐analyses, and decided post hoc to explore differences between the two models using the fixed‐effect model in sensitivity analysis (if more than one trial provided data for meta‐analysis). </p> </section> </section> <section id="CD012814-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses.</p> <p> <ul id="CD012814-list-0012"> <li> <p>Trials at low risk of bias compared to trials at high risk of bias (as defined previously).</p> </li> <li> <p>Surgical margin status (histologically cancer negative compared to histologically cancer positive). </p> </li> <li> <p>Status of regional lymph node (negative compared to positive).</p> </li> <li> <p>Location of tumour (intrahepatic compared to extrahepatic).</p> </li> <li> <p>Type of adjuvant chemotherapy regimen (gemcitabine‐based compared to 5‐FU based).</p> </li> </ul> </p> <p>We assessed subgroup differences by interaction tests and reported the results of subgroup analyses quoting the Chi<sup>2</sup> test and P value, the interaction test, and the I<sup>2</sup> statistic value whenever data were available. </p> </section> <section id="CD012814-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to apply 'best‐worst‐case' and 'worst‐best‐case' scenarios based on the outcomes all‐cause mortality, quality of life, and serious adverse events. </p> <p>We also used the fixed‐effect model to conduct meta‐analyses. We planned to report both the fixed‐effect and random‐effects models if results differed. </p> <p>We used Trial Sequential Analysis to assess imprecision (<a href="./references#CD012814-bbs2-0063" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014</a>), and compared the result with our GRADE assessment of imprecision. </p> <section id="CD012814-sec-0048"> <h5 class="title">Trial Sequential Analyses</h5> <p>We applied Trial Sequential Analysis (TSA) (<a href="./references#CD012814-bbs2-0100" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017. Available from ctu.dk/tsa/learn-more.">Thorlund 2017</a>; <a href="./references#CD012814-bbs2-0102" title="Copenhagen Trial UnitTSA - Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2017. Available at ctu.dk/tsa/downloads/.">TSA 2017</a>) to control random errors in our meta‐analysis (<a href="./references#CD012814-bbs2-0032" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61:763-9.">Brok 2008</a>; <a href="./references#CD012814-bbs2-0106" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD012814-bbs2-0033" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analyses may be inconclusive - Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98.">Brok 2009</a>; <a href="./references#CD012814-bbs2-0098" title="ThorlundK , DevereauxPJ , WetterslevJ , GuyattG , IoannidisJP , ThabaneL , et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology2009;38(1):276-86.">Thorlund 2009</a>; <a href="./references#CD012814-bbs2-0107" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>; <a href="./references#CD012814-bbs2-0099" title="ThorlundK , AnemaA , MillsE . Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology2010;2:57-66.">Thorlund 2010</a>; <a href="./references#CD012814-bbs2-0108" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). We calculated the required information size (i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) which should also consider the diversity observed in the meta‐analysis (<a href="./references#CD012814-bbs2-0106" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD012814-bbs2-0107" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology2009;9:86.">Wetterslev 2009</a>; <a href="./references#CD012814-bbs2-0108" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). </p> <p>We calculated the required information size for dichotomous outcomes based on the event proportion in the control group of the included trials; assumption of an a priori risk ratio of 10%; a risk of type I error of 2.5% for both primary and secondary outcomes as we have three outcomes of both (<a href="./references#CD012814-bbs2-0063" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120.">Jakobsen 2014</a>); a risk of type II error of 10% (power 90%); and the observed diversity of the meta‐analysis (<a href="./references#CD012814-bbs2-0108" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39.">Wetterslev 2017</a>). We planned also to conduct a TSA using the risk ratio in trials at low risk of bias, but as we found no such trials, this analysis will have to wait for their appearance. In future updates, for continuous outcomes, we will estimate the required information size based on the standard deviation observed in the control group of the meta‐analysis and a minimal relevant difference of 50% of this standard deviation, and the observed diversity in the trials in the meta‐analysis. For hazard ratio (HR), we will conduct robustness analyses by changing them into risk ratio as described above, or we will use software that can handle HRs (<a href="./references#CD012814-bbs2-0073" title="MiladinovicJ , HozI , DjulbegovicD . Trial sequential boundaries for cumulative meta-analysis. Stata Journal2013;13(11):77-91.">Miladinovic 2013</a>). </p> <p>We added the trials according to year of publication. Based on the required information size, we constructed trial sequential monitoring boundaries (<a href="./references#CD012814-bbs2-0106" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>; <a href="./references#CD012814-bbs2-0100" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017. Available from ctu.dk/tsa/learn-more.">Thorlund 2017</a>). These boundaries determine the statistical inference that one may draw regarding the cumulative meta‐analysis that has not reached the required information size; if the trial sequential monitoring boundary is crossed before the required information size is reached, firm evidence may perhaps be established, and further trials may be superfluous. In contrast, if the boundary is not surpassed, it is most likely necessary to continue conducting trials to detect or reject a certain intervention effect. This can be determined by assessing whether or not the cumulative Z‐curve crosses the trial sequential monitoring boundary for futility (<a href="./references#CD012814-bbs2-0106" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75.">Wetterslev 2008</a>). We conducted TSA using software from the Copenhagen Trial Unit (<a href="./references#CD012814-bbs2-0100" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User Manual for Trial Sequential Analysis (TSA); 2nd edition. Copenhagen Trial Unit, 2017. Available from ctu.dk/tsa/learn-more.">Thorlund 2017</a>; <a href="./references#CD012814-bbs2-0102" title="Copenhagen Trial UnitTSA - Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2017. Available at ctu.dk/tsa/downloads/.">TSA 2017</a>). </p> <p>We reported and compared the results with TSA as sensitivity analysis to imprecision assessed by GRADE. We downgrade imprecision in TSA by two levels if the accrued number of participants is below 50% of the diversity‐adjusted required information size (DARIS), and one level if it is between 50% and 100% of DARIS. We do not downgrade if the cumulative Z‐curve crosses the monitoring boundaries for benefit, harm, or futility, or if DARIS is reached. </p> </section> </section> <section id="CD012814-sec-0049"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created two summary of findings tables with all review outcomes, with data collected at the longest follow‐up (all‐cause mortality (median follow‐up range 46.5 to 79.4 months), serious adverse events (median follow‐up 79.4 months), health‐related quality of life, cancer‐related mortality (death from cancer), time to recurrence of the tumour, and non‐serious adverse events) obtained from the included trials using <a href="./references#CD012814-bbs2-0043" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed March 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> software (<a href="./references#CD012814-bbs2-0043" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed March 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed (<a href="./references#CD012814-bbs2-0043" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed March 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). The certainty of a body of evidence considers within‐study risk of bias, indirectness of the evidence, heterogeneity of the data, imprecision of effect estimates, and risk of publication bias (<a href="./references#CD012814-bbs2-0028" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6. [PMID: 21208779]">Balshem 2011</a>; <a href="./references#CD012814-bbs2-0045" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395-400. [PMID: 21194891]">Guyatt 2011b</a>; <a href="./references#CD012814-bbs2-0046" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso-CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407-15. [PMID: 21247734]">Guyatt 2011c</a>; <a href="./references#CD012814-bbs2-0047" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology2011;64(12):1277-82. [PMID: 21802904]">Guyatt 2011d</a>; <a href="./references#CD012814-bbs2-0048" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [PMID: 21839614]">Guyatt 2011e</a>; <a href="./references#CD012814-bbs2-0049" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology2011;64(12):1294-302. [PMID: 21803546]">Guyatt 2011f</a>; <a href="./references#CD012814-bbs2-0050" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology2011;64(12):1303-10. [PMID: 21802903]">Guyatt 2011g</a>; <a href="./references#CD012814-bbs2-0051" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso-CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311-6. [PMID: 21802902]">Guyatt 2011h</a>; <a href="./references#CD012814-bbs2-0044" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [PMID: 21195583]">Guyatt 2011a</a>; <a href="./references#CD012814-bbs2-0053" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables - binary outcomes. Journal of Clinical Epidemiology2013;66(2):158-72. [PMID: 22609141]">Guyatt 2013b</a>; <a href="./references#CD012814-bbs2-0054" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles - continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173-83. [PMID: 23116689]">Guyatt 2013c</a>; <a href="./references#CD012814-bbs2-0055" title="GuyattG , AndrewsJ , OxmanAD , AldersonP , DahmP , Falck-YtterY , et al. GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology2013;66(7):719-25.">Guyatt 2013d</a>; <a href="./references#CD012814-bbs2-0052" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso-CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151-7. [PMID: 22542023]">Guyatt 2013a</a>; <a href="./references#CD012814-bbs2-0075" title="MustafaRA , SantessoN , BrozekJ , AklEA , WalterSD , NormanG , et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology2013;66(7):736-42. [PMID: 23623694]">Mustafa 2013</a>; <a href="./references#CD012814-bbs2-0056" title="GuyattGH , EbrahimS , Alonso-CoelloP , JohnstonBC , MathioudakisAG , BrielM , et al. GRADE guidelines: 17. Assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology2017;87:14-22. [PMID: 28529188]">Guyatt 2017</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012814-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012814-sec-0050"></div> <section id="CD012814-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD012814-sec-0052"> <h4 class="title">Results of the search</h4> <p>Our searches identified 472 records (<a href="#CD012814-fig-0001">Figure 1</a>). We found and removed 114 duplicate records. After examining the titles and abstracts of the remaining 358 records, we selected 26 records for full‐text review. We found five randomised clinical trials that fulfilled our inclusion criteria (see <a href="#CD012814-sec-0053">Included studies</a>; <a href="./references#CD012814-sec-0113" title="">Characteristics of included studies</a>). </p> <div class="figure" id="CD012814-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. Date of search 28 April 2021." data-id="CD012814-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. Date of search 28 April 2021.</p> </div> </div> </div> <p>We excluded a total of 15 studies (see <a href="./references#CD012814-bbs1-0002" title="">Excluded studies</a>; <a href="./references#CD012814-sec-0114" title="">Characteristics of excluded studies</a>). We did not find any quasi‐randomised or observational studies describing harmful effects of the intervention. </p> <p>We identified six ongoing studies (see <a href="./references#CD012814-bbs1-0003" title="">Ongoing studies</a>; <a href="./references#CD012814-sec-0115" title="">Characteristics of ongoing studies</a>). We did not identify any unpublished studies. </p> </section> <section id="CD012814-sec-0053"> <h4 class="title">Included studies</h4> <p>We included five randomised clinical trials (see <a href="./references#CD012814-sec-0113" title="">Characteristics of included studies</a>) (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>; <a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>; <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>). One trial recruited only participants with cholangiocarcinoma (<a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>). The other four trials recruited participants with cholangiocarcinoma and participants with gallbladder cancer (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>; <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>). Two of these four trials provided separate information on participants with cholangiocarcinoma in their reports (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>). The other two trials did not provide information specific to participants with cholangiocarcinoma in their reports (<a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>). We contacted the authors of <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a> and <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a> to obtain specific information on participants with cholangiocarcinoma alone. The authors of <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a> provided the requested information, whilst the authors of <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a> did not reply to our requests. As a result, we combined data on participants with cholangiocarcinoma and gallbladder cancer from Kobayashi and colleagues in our analyses. </p> <p>The five included trials involved a total of 931 participants with cholangiocarcinoma and were conducted in France, Japan, and the United Kingdom; all trials had a parallel‐group design. Four trials (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>; <a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>; <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>), with 867 participants (who underwent surgery), compared the efficacy of postoperative adjuvant chemotherapy (mitomycin‐C and 5‐fluorouracil (5‐FU); gemcitabine; gemcitabine plus oxaliplatin; or capecitabine) versus no postoperative adjuvant chemotherapy. The remaining trial was a phase II trial, with 64 participants, comparing two different regimens of postoperative adjuvant chemotherapy (S‐1 versus gemcitabine) (<a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>). All participants underwent surgery before the postoperative treatment. </p> <p><a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a> randomised 508 trial participants with resected pancreatic, bile duct, gallbladder, or ampulla of Vater carcinomas to either the mitomycin‐C and 5‐FU experimental intervention group or the control intervention group, who received no postoperative adjuvant chemotherapy (surgery alone). There were 118 trial participants with bile duct carcinoma, that is cholangiocarcinoma. The trial randomised participants from April 1986 to June 1992 in 31 centres in Japan. The trial followed up all participants for five years. </p> <p><a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a> randomised 225 participants with resected extrahepatic cholangiocarcinoma (recruited from 1 September 2007 to 31 January 2011) at 48 hospitals in Japan. The trial participants were randomised in a 1:1 ratio to postoperative adjuvant gemcitabine (experimental intervention group) versus no postoperative adjuvant chemotherapy (surgery alone) (control intervention group). The trial followed up all but two participants for a median of 79.4 months. </p> <p><a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a> randomised 196 participants with macroscopically resected biliary tract cancer, which included cholangiocarcinoma and gallbladder carcinoma (enrolled from July 2009 and February 2014) at 33 centres across France. There were 156 participants with cholangiocarcinoma. The trial participants (with macroscopically resected cholangiocarcinoma) were randomly assigned (1:1) within three months after resection to receive either postoperative adjuvant chemotherapy GEMOX (gemcitabine plus oxaliplatin) regimen (experimental intervention group) or surveillance with no postoperative adjuvant chemotherapy (control intervention group). The trial followed up all participants for a median of 46.5 months (95% CI 42.6 to 49.3 months). </p> <p><a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a> randomised 447 participants who had undergone macroscopically resection for cholangiocarcinoma and muscle‐invasion gallbladder cancer (from 15 March 2006 to 4 December 2014) across 44 specialist hepato‐pancreato‐biliary centres in the United Kingdom. The trial participants were randomly assigned (1:1) to receive postoperative adjuvant oral capecitabine (experimental intervention group) versus observation (no postoperative adjuvant chemotherapy) (control intervention group) commencing within 16 weeks after surgery. There were 368 participants with cholangiocarcinoma (284 extrahepatic and 84 intrahepatic cholangiocarcinoma). The trial followed up all participants for a median of 60 months (interquartile range (IQR) 37 to 60). </p> <p><a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a> randomised 70 participants who had undergone major hepatectomy for biliary tract cancer, which included intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, and carcinoma of gallbladder (from February 2013 to June 2016) at centres across Japan. There were 64 participants with cholangiocarcinoma. The participants were randomly assigned (1:1) to receive postoperative adjuvant chemotherapy S‐1 (experimental intervention group) versus gemcitabine (control intervention group). The authors reported one‐ and two‐year survival rates based on all participants, but did not report the follow‐up time. There were no losses to follow‐up at the end of the study. </p> <p>There were no losses to follow‐up in four trials (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>; <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>). Three included trials used intention‐to‐treat analyses (<a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>). One trial used a per‐protocol analysis, although there were no loss to follow‐up (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>). The fifth trial had one loss to follow‐up in each group (<a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>); however, the outcomes of these two participants were not described, therefore it was unclear whether or not this trial used intention‐to‐treat analysis. </p> </section> <section id="CD012814-sec-0054"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 studies that did not fulfil our inclusion criteria (see <a href="./references#CD012814-sec-0114" title="">Characteristics of excluded studies</a>) (<a href="./references#CD012814-bbs2-0011" title="LimKH , OhDY , ChieEK , JangJY , ImSA , KimTY , et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer2009;9:345. [PMID: 19781103]">Lim 2009</a>; <a href="./references#CD012814-bbs2-0006" title="Di GirolamoS , NobiliE , DerenziniE , deRosaF , AgostiniV , ErcolaniG , et al. Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. Journal of Clinical Oncology2011;29(4 Suppl):299. ">Di Girolamo 2011</a>; <a href="./references#CD012814-bbs2-0007" title="GhidiniM , LampisA , BraconiC , TrevisaniF , CheongIH , HahneJC , et al. Retrospective analysis of the role of adjuvant chemotherapy and microRNAs expression in resected cholangiocarcinomas (CCAs). Annals of Oncology2015;26(Suppl 6):L22. ">Ghidini 2015</a>; <a href="./references#CD012814-bbs2-0008" title="HoehnRS , WimaK , ErtelAE , MeierA , AhmadSA , ShahSA , et al. Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma. Annals of Surgical Oncology2015;22(Suppl 3):S1133-9. [PMID: 25976862]">Hoehn 2015</a>; <a href="./references#CD012814-bbs2-0019" title="ToyokiY , IshidoK , KudoD , KimuraN , HakamadaK . Adjuvant chemotherapy using S-1 improves survival in patients with resected advanced extra-hepatic bile duct cancer: a propensity score matching analysis. Journal of Clinical Oncology2015;33(15 Suppl):e15170. ">Toyoki 2015</a>; <a href="./references#CD012814-bbs2-0009" title="KimYS , OhSY , GoSI , KangJH , ParkI , SongHN , et al. The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas. Cancer Chemotherapy and Pharmacology2017;79(1):99-106. [PMID: 27928598]">Kim 2017</a>; <a href="./references#CD012814-bbs2-0012" title="MizunoT , EbataT , YokoyamaY , IgamiT , SugawaraG , YamaguchiJ , et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis. Surgery Today2017;47(2):182-92. [PMID: 27194019]">Mizuno 2017</a>; <a href="./references#CD012814-bbs2-0016" title="OkabayashiT , ShimaY , IwataJ , MoritaS , SumiyoshiT , SuiK , et al. Characterization of prognostic factors and the efficacy of adjuvant s-1 chemotherapy in patients with post-surgery extrahepatic bile duct cancer. Anticancer Research2017;37(12):7049-56. [PMID: 29187494]">Okabayashi 2017</a>; <a href="./references#CD012814-bbs2-0017" title="SchweitzerN , WeberT , KirsteinMM , FischerM , KratzelAM , Reineke-PlaassT , et al. The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. Journal of Cancer Research and Clinical Oncology2017;143(7):1347-55. [PMID: 28314929]">Schweitzer 2017</a>; <a href="./references#CD012814-bbs2-0020" title="WooSM , Yoon K-A, HongEK , ParkWS , Han S-S, ParkSJ , et al. A phase II study of gemcitabine as adjuvant treatment for biliary tract cancer after surgical resection. Journal of Clinical Oncology2017;35(4 Suppl):330. ">Woo 2017</a>; <a href="./references#CD012814-bbs2-0010" title="KrasnickBA , JinLX , Davidson JT 4th, SanfordDE , EthunCG , PawlikTM , et al. Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: a multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology2018;117(3):363-71. [PMID: 29284072]">Krasnick 2018</a>; <a href="./references#CD012814-bbs2-0013" title="NassourI , MokdadAA , PorembkaMR , ChotiMA , PolancoPM , MansourJC , et al. Adjuvant therapy is associated with improved survival in resected perihilar cholangiocarcinoma: a propensity matched study. Annals of Surgical Oncology2018;25(5):1193-201. [PMID: 29488187]">Nassour 2018</a>; <a href="./references#CD012814-bbs2-0018" title="SiebenhunerAR , SeifertH , BachmannH , SeifertB , WinderT , FeilchenfeldtJ , et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer2018;18(1):72. [PMID: 29325521]">Siebenhuner 2018</a>; <a href="./references#CD012814-bbs2-0014" title="NCT02798510. Clinical trial of adjuvant chemotherapy followed by concurrent chemoradiotherapy compared with adjuvant chemotherapy alone in patients with gallbladder carcinoma and extrahepatic cholangiocarcinoma. clinicaltrials.gov/ct2/show/NCT02798510 (first received 14 June 2016). ">NCT02798510</a>; <a href="./references#CD012814-bbs2-0015" title="NCT03081039. A study of cisplatin or carboplatin with gemcitabine versus gemcitabine alone as adjuvant therapy in patients with resected or ablation intra-hepatic cholangiocarcinoma. clinicaltrials.gov/ct2/show/NCT03081039 (first received 15 March 2017). ">NCT03081039</a>). Eleven studies were retrospective (<a href="./references#CD012814-bbs2-0011" title="LimKH , OhDY , ChieEK , JangJY , ImSA , KimTY , et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer2009;9:345. [PMID: 19781103]">Lim 2009</a>; <a href="./references#CD012814-bbs2-0006" title="Di GirolamoS , NobiliE , DerenziniE , deRosaF , AgostiniV , ErcolaniG , et al. Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. Journal of Clinical Oncology2011;29(4 Suppl):299. ">Di Girolamo 2011</a>; <a href="./references#CD012814-bbs2-0007" title="GhidiniM , LampisA , BraconiC , TrevisaniF , CheongIH , HahneJC , et al. Retrospective analysis of the role of adjuvant chemotherapy and microRNAs expression in resected cholangiocarcinomas (CCAs). Annals of Oncology2015;26(Suppl 6):L22. ">Ghidini 2015</a>; <a href="./references#CD012814-bbs2-0008" title="HoehnRS , WimaK , ErtelAE , MeierA , AhmadSA , ShahSA , et al. Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma. Annals of Surgical Oncology2015;22(Suppl 3):S1133-9. [PMID: 25976862]">Hoehn 2015</a>; <a href="./references#CD012814-bbs2-0019" title="ToyokiY , IshidoK , KudoD , KimuraN , HakamadaK . Adjuvant chemotherapy using S-1 improves survival in patients with resected advanced extra-hepatic bile duct cancer: a propensity score matching analysis. Journal of Clinical Oncology2015;33(15 Suppl):e15170. ">Toyoki 2015</a>; <a href="./references#CD012814-bbs2-0009" title="KimYS , OhSY , GoSI , KangJH , ParkI , SongHN , et al. The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas. Cancer Chemotherapy and Pharmacology2017;79(1):99-106. [PMID: 27928598]">Kim 2017</a>; <a href="./references#CD012814-bbs2-0012" title="MizunoT , EbataT , YokoyamaY , IgamiT , SugawaraG , YamaguchiJ , et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis. Surgery Today2017;47(2):182-92. [PMID: 27194019]">Mizuno 2017</a>; <a href="./references#CD012814-bbs2-0016" title="OkabayashiT , ShimaY , IwataJ , MoritaS , SumiyoshiT , SuiK , et al. Characterization of prognostic factors and the efficacy of adjuvant s-1 chemotherapy in patients with post-surgery extrahepatic bile duct cancer. Anticancer Research2017;37(12):7049-56. [PMID: 29187494]">Okabayashi 2017</a>; <a href="./references#CD012814-bbs2-0017" title="SchweitzerN , WeberT , KirsteinMM , FischerM , KratzelAM , Reineke-PlaassT , et al. The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. Journal of Cancer Research and Clinical Oncology2017;143(7):1347-55. [PMID: 28314929]">Schweitzer 2017</a>; <a href="./references#CD012814-bbs2-0010" title="KrasnickBA , JinLX , Davidson JT 4th, SanfordDE , EthunCG , PawlikTM , et al. Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: a multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium. Journal of Surgical Oncology2018;117(3):363-71. [PMID: 29284072]">Krasnick 2018</a>; <a href="./references#CD012814-bbs2-0013" title="NassourI , MokdadAA , PorembkaMR , ChotiMA , PolancoPM , MansourJC , et al. Adjuvant therapy is associated with improved survival in resected perihilar cholangiocarcinoma: a propensity matched study. Annals of Surgical Oncology2018;25(5):1193-201. [PMID: 29488187]">Nassour 2018</a>); one study was designed to determine whether adjuvant concurrent chemoradiotherapy improved overall survival (<a href="./references#CD012814-bbs2-0014" title="NCT02798510. Clinical trial of adjuvant chemotherapy followed by concurrent chemoradiotherapy compared with adjuvant chemotherapy alone in patients with gallbladder carcinoma and extrahepatic cholangiocarcinoma. clinicaltrials.gov/ct2/show/NCT02798510 (first received 14 June 2016). ">NCT02798510</a>); two studies were phase II studies in which all participants received postoperative adjuvant chemotherapy (<a href="./references#CD012814-bbs2-0020" title="WooSM , Yoon K-A, HongEK , ParkWS , Han S-S, ParkSJ , et al. A phase II study of gemcitabine as adjuvant treatment for biliary tract cancer after surgical resection. Journal of Clinical Oncology2017;35(4 Suppl):330. ">Woo 2017</a>; <a href="./references#CD012814-bbs2-0018" title="SiebenhunerAR , SeifertH , BachmannH , SeifertB , WinderT , FeilchenfeldtJ , et al. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: a prospective single center phase II study. BMC Cancer2018;18(1):72. [PMID: 29325521]">Siebenhuner 2018</a>); and one study was withdrawn (<a href="./references#CD012814-bbs2-0015" title="NCT03081039. A study of cisplatin or carboplatin with gemcitabine versus gemcitabine alone as adjuvant therapy in patients with resected or ablation intra-hepatic cholangiocarcinoma. clinicaltrials.gov/ct2/show/NCT03081039 (first received 15 March 2017). ">NCT03081039</a>). </p> <p>Amongst these, we did not find any relevant quasi‐randomised or other non‐randomised studies reporting on adverse events. </p> </section> <section id="CD012814-sec-0055"> <h4 class="title">Ongoing studies</h4> <p>We identified six ongoing studies that appear to meet our inclusion criteria (see <a href="./references#CD012814-sec-0115" title="">Characteristics of ongoing studies</a>) (<a href="./references#CD012814-bbs2-0025" title="SteinA , ArnoldD , BridgewaterJ , GoldsteinD , JensenLH , KlumpenHJ , et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer2015;15:564. [PMID: 26228433]">Stein 2015</a>; <a href="./references#CD012814-bbs2-0021" title="NakachiK , KonishiM , IkedaM , MizusawaJ , EbaJ , OkusakaT , et al. A randomized phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Japanese Journal of Clinical Oncology2018;48(4):392-5. [PMID: 29462482]">Nakachi 2018</a>; <a href="./references#CD012814-bbs2-0022" title="NCT02548195. Oxaliplatin+gemcitabine vs capecitabine as adjuvant therapy for intrahepatic cholangiocarcinoma. clinicaltrials.gov/ct2/show/NCT02548195 (first received 14 September 2015). ">NCT02548195</a>; <a href="./references#CD012814-bbs2-0023" title="NCT03079427. Adjuvant capecitabine vs gemcitabine plus cisplatin in resected extrahepatic cholangiocarcinoma. clinicaltrials.gov/ct2/show/NCT03079427 (first received 14 March 2017). ">NCT03079427</a>; <a href="./references#CD012814-bbs2-0024" title="NCT03609489. A study to investigate apatinib combined capecitabine on adjuvant therapy of biliary carcinoma. clinicaltrials.gov/ct2/show/NCT03609489 (first received 1 August 2018). ">NCT03609489</a>; <a href="./references#CD012814-bbs2-0026" title="TCTR20161101003. A randomized controlled trial of gemcitabine alone versus gemcitabine plus cisplatin as an adjuvant chemotherapy after curative intent resection of cholangiocarcinoma. www.thaiclinicaltrials.org/show/TCTR20161101003 (first received 31 October 2016). ">TCTR20161101003</a>). As of 9 July 2021, no further information than that described below was available. </p> <p> <ul id="CD012814-list-0013"> <li> <p><a href="./references#CD012814-bbs2-0025" title="SteinA , ArnoldD , BridgewaterJ , GoldsteinD , JensenLH , KlumpenHJ , et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer2015;15:564. [PMID: 26228433]">Stein 2015</a> has planned a multicentre, two‐stage randomised controlled phase III trial, comparing postoperative adjuvant chemotherapy with gemcitabine plus cisplatin versus capecitabine after curative‐intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA‐1 Trial). The primary outcome is disease‐free survival. The estimated enrolment is 781 participants. The trial is still recruiting. Last follow‐up date: 23 September 2020. </p> </li> <li> <p><a href="./references#CD012814-bbs2-0021" title="NakachiK , KonishiM , IkedaM , MizusawaJ , EbaJ , OkusakaT , et al. A randomized phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Japanese Journal of Clinical Oncology2018;48(4):392-5. [PMID: 29462482]">Nakachi 2018</a> has planned a randomised phase III trial comparing postoperative adjuvant chemotherapy with S‐1 versus surgery alone (no postoperative adjuvant chemotherapy) in individuals with resectable biliary tract cancer (JCOG1202: aSCOT; Japan Clinical Oncology Group Study: Adjuvant S‐1 for Cholangiocarcinoma Trial). The primary outcome is overall survival. The planned total sample size is 440. The trial is still recruiting. </p> </li> <li> <p><a href="./references#CD012814-bbs2-0022" title="NCT02548195. Oxaliplatin+gemcitabine vs capecitabine as adjuvant therapy for intrahepatic cholangiocarcinoma. clinicaltrials.gov/ct2/show/NCT02548195 (first received 14 September 2015). ">NCT02548195</a> is a randomised, open‐label, phase III trial comparing oxaliplatin plus gemcitabine versus capecitabine alone as postoperative adjuvant treatment in the prevention of recurrence of intrahepatic cholangiocarcinoma. The primary outcome is recurrence‐free survival. The estimated enrolment is 286 participants. The trial is still recruiting. Last follow‐up date: 14 September 2015. </p> </li> <li> <p><a href="./references#CD012814-bbs2-0023" title="NCT03079427. Adjuvant capecitabine vs gemcitabine plus cisplatin in resected extrahepatic cholangiocarcinoma. clinicaltrials.gov/ct2/show/NCT03079427 (first received 14 March 2017). ">NCT03079427</a> is a randomised, open‐label, phase II trial of postoperative adjuvant capecitabine versus gemcitabine plus cisplatin in individuals with resected extrahepatic cholangiocarcinoma with regional lymph node metastasis. The primary outcome is two‐year disease‐free survival. The estimated enrolment is 100 participants. The trial is still recruiting. Last follow‐up date: 16 June 2020. </p> </li> <li> <p><a href="./references#CD012814-bbs2-0024" title="NCT03609489. A study to investigate apatinib combined capecitabine on adjuvant therapy of biliary carcinoma. clinicaltrials.gov/ct2/show/NCT03609489 (first received 1 August 2018). ">NCT03609489</a> is a randomised, open‐label, phase II trial of postoperative apatinib (a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor‐2) plus capecitabine versus capecitabine as adjuvant treatment for individuals with surgical resection for histologically confirmed biliary tract cancer. The primary outcome is progression‐free survival. The estimated enrolment is 40 participants. This trial is not yet recruiting. Last follow‐up date: 9 August 2018. </p> </li> <li> <p><a href="./references#CD012814-bbs2-0026" title="TCTR20161101003. A randomized controlled trial of gemcitabine alone versus gemcitabine plus cisplatin as an adjuvant chemotherapy after curative intent resection of cholangiocarcinoma. www.thaiclinicaltrials.org/show/TCTR20161101003 (first received 31 October 2016). ">TCTR20161101003</a> is a randomised, single‐blinded, phase III trial of gemcitabine alone versus gemcitabine plus cisplatin as adjuvant chemotherapy after curative‐intent resection of cholangiocarcinoma. The primary outcome is overall survival. The estimated enrolment was not available. The trial is still recruiting. Last follow‐up date: 10 August 2020. </p> </li> </ul> </p> </section> </section> <section id="CD012814-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias of the included trials. For graphical presentation, see <a href="#CD012814-fig-0002">Figure 2</a> and <a href="#CD012814-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012814-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012814-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012814-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012814-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012814-sec-0057"> <h4 class="title">Allocation</h4> <p>Both allocation sequence generation and allocation concealment were clearly reported in two trials (<a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>), whereas it was not described in the other three trials (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>; <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>). </p> </section> <section id="CD012814-sec-0058"> <h4 class="title">Blinding</h4> <p>We judged all trials to be at high risk of performance and detection bias, since four trials were described as "open label" trials (<a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>; <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>), and the remaining trial did not provide information regarding blinding (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>), but it was likely that the blinding was broken because participants in the control group received neither treatment nor placebo. </p> </section> <section id="CD012814-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>There was a low risk of attrition bias in all of the included trials.</p> </section> <section id="CD012814-sec-0060"> <h4 class="title">Selective reporting</h4> <p>We judged four trials to be at low risk of reporting bias (<a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>; <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>), as all predefined outcomes in their respective protocols were reported in the results (<a href="./references#CD012814-bbs2-0103" title="UMIN000000820. Randomised phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resectable bile duct cancer. upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000983 (first received 20 July 2007).">UMIN000000820</a>; <a href="./references#CD012814-bbs2-0080" title="NCT01313377. Gemcitabine hydrochloride and oxaliplatin or observation in treating patients with biliary tract cancer that has been removed by surgery. clinicaltrials.gov/ct2/show/NCT01313377 (first received 11 March 2011).">NCT01313377</a>; <a href="./references#CD012814-bbs2-0081" title="NCT01815307. Phase II study of gemcitabine versus S-1 adjuvant therapy after hemihepatectomy for biliary tract cancer. clinicaltrials.gov/ct2/show/NCT01815307 (first received 21 March 2013).">NCT01815307</a>; <a href="./references#CD012814-bbs2-0079" title="NCT00363584. Capecitabine or observation after surgery in treating patients with biliary tract cancer. clinicaltrials.gov/ct2/show/NCT00363584 (first received 15 August 2006).">NCT00363584</a>). We judged the remaining trial as at unclear risk of reporting bias as the protocol of the trial was not available (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>). </p> </section> <section id="CD012814-sec-0061"> <h4 class="title">Other potential sources of bias</h4> <p>We found no evidence of any other biases in the included trials.</p> </section> </section> <section id="CD012814-sec-0062"> <h3 class="title" id="CD012814-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD012814-tbl-0001"><b>Summary of findings 1</b> Adjuvant chemotherapy compared with no chemotherapy for resectable cholangiocarcinoma</a>; <a href="./full#CD012814-tbl-0002"><b>Summary of findings 2</b> Adjuvant S‐1 compared to gemcitabine for resectable cholangiocarcinoma</a> </p> <p>Four included trials compared postoperative adjuvant chemotherapy following curative‐intent resection versus no postoperative adjuvant chemotherapy (surgical resection alone). See <a href="#CD012814-sec-0053">Included studies</a>; <a href="./references#CD012814-sec-0113" title="">Characteristics of included studies</a>; and <a href="./full#CD012814-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012814-sec-0063"> <h4 class="title">Adjuvant chemotherapy versus no adjuvant chemotherapy</h4> <section id="CD012814-sec-0064"> <h5 class="title">Primary outcomes</h5> <section id="CD012814-sec-0065"> <h6 class="title">All‐cause mortality</h6> <p>All four trials reported five‐year survival with the number of people with cholangiocarcinoma who were alive. We converted these data into number of people who died to obtain all‐cause mortality at five years. The median follow‐up time was 46.5 months for <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>, 60 months for <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>, and 79.4 months for <a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>, and at least five years for all trial participants in <a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>. There seemed to be little to no difference in all‐cause mortality at five years between postoperative adjuvant chemotherapy and no postoperative adjuvant chemotherapy (RR 0.92, 95% CI 0.84 to 1.01; 4 trials, 867 participants, I<sup>2</sup> = 0%, <a href="./references#CD012814-fig-0005" title="">Analysis 1.1</a>, very low‐certainty evidence). </p> <section id="CD012814-sec-0066"> <p><b>Sensitivity analysis</b></p> <p>We observed similar findings with the TSA: the TSA‐adjusted RR was 0.92 (0.74 to 1.16). The required information size was not met (3473 participants; <a href="#CD012814-fig-0004">Figure 4</a>). As only 25% of the required information size was accrued, we downgraded imprecision by two levels with TSA unlike our assessment of imprecsion by one level with GRADE. </p> <div class="figure" id="CD012814-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial Sequential Analysis (TSA) on all‐cause mortality Four trials provided data on all‐cause mortality. The diversity‐adjusted required information size (DARIS) was calculated based on event proportion in the control group of 59.3% (255/430), relative risk reduction (RRR) of 10%, type I error of 2.5%, type II error of 10% (90% power), and heterogeneity correction based on model variance (trial diversity was 0%). The required information size was 3473 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward‐sloping lines), or futility (red outward lines). The accrued number of randomised participants is only 25% of the DARIS. The green dashed lines show conventional boundaries (2.5%). The TSA‐adjusted risk ratio was 0.92 (TSA‐adjusted confidence interval 0.74 to 1.16); two‐sided hypothesis testing, O’Brien‐Fleming α‐spending function." data-id="CD012814-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial Sequential Analysis (TSA) on all‐cause mortality</b> </p> <p>Four trials provided data on all‐cause mortality. The diversity‐adjusted required information size (DARIS) was calculated based on event proportion in the control group of 59.3% (255/430), relative risk reduction (RRR) of 10%, type I error of 2.5%, type II error of 10% (90% power), and heterogeneity correction based on model variance (trial diversity was 0%). The required information size was 3473 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward‐sloping lines), or futility (red outward lines). The accrued number of randomised participants is only 25% of the DARIS. The green dashed lines show conventional boundaries (2.5%). The TSA‐adjusted risk ratio was 0.92 (TSA‐adjusted confidence interval 0.74 to 1.16); two‐sided hypothesis testing, O’Brien‐Fleming α‐spending function. </p> </div> </div> </div> </section> </section> <section id="CD012814-sec-0067"> <h6 class="title">Serious adverse events</h6> <p>Only one trial focused on adverse events in participants with cholangiocarcinoma who received postoperative adjuvant chemotherapy (<a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>), finding that postoperative adjuvant chemotherapy increased serious adverse events (RR 17.82, 95% CI 2.43 to 130.82; 1 trial, 219 participants, I<sup>2</sup> = 0%, very low‐certainty evidence). </p> <p><a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a> found that the postoperative adjuvant chemotherapy (gemcitabine) group had more grade 3/4 haematologic toxicities compared with the no postoperative adjuvant chemotherapy (observation) group (<a href="#CD012814-tbl-0003">Table 1</a>). The risk ratio was 15.5 (95% CI 3.8 to 62.9) for abnormal leucocyte level and 15.5 (95% CI 5.8 to 40.9) for abnormal neutrophil level. Non‐haematological adverse events were rare and comparable between the two groups. </p> <div class="table" id="CD012814-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Grade 3/4 haematologic adverse events</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants<br/>with an event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Proportion (%)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leucocytes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant gemcitabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutrophils</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant gemcitabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4</p> </td> </tr> </tbody> </table> </div> <p>The trials by <a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>, <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>, and <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a> did not report data on adverse events for participants with cholangiocarcinoma. </p> </section> <section id="CD012814-sec-0068"> <h6 class="title">Health‐related quality of life</h6> <p>Two trials reported some data on health‐related quality of life (<a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>); however, the reported information did not focus specifically on participants with cholangiocarcinoma alone, but on participants with cholangiocarcinoma and carcinoma of the gallbladder together. </p> <p><a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a> reported that there was no difference in time to definitive deterioration of global health‐related quality of life, defined as the time between randomisation and worsening of global, physical functioning, or fatigue using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐C30 scores of at least 5 points (log‐rank P value = 0.39), and physical functioning (log‐rank P value = 0.15) between those who received postoperative adjuvant GEMOX (gemcitabine and oxaliplatin) and those who did not. </p> <p><a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a> assessed each quality of life domain by comparison of standardised area under the curve via a Mann‐Whitney test, reporting that trial participants who received postoperative adjuvant capecitabine had worse social functioning compared with those who did not, with a median standardised area under the curve of 76.2 (IQR 56.9 to 91.7) in the capecitabine group and 83.3 (IQR 64.6 to 95.8) in the observation (no postoperative adjuvant chemotherapy) group (P = 0.006). </p> </section> </section> <section id="CD012814-sec-0069"> <h5 class="title">Secondary outcomes</h5> <section id="CD012814-sec-0070"> <h6 class="title">Cancer‐related mortality (death from cancer)</h6> <p>None of the included trials planned to assess this outcome.</p> </section> <section id="CD012814-sec-0071"> <h6 class="title">Time to recurrence of the tumour</h6> <p>None of the included trials planned to assess this outcome.</p> </section> <section id="CD012814-sec-0072"> <h6 class="title">Non‐serious adverse events</h6> <p>None of the included trials planned to assess this outcome.</p> </section> </section> <section id="CD012814-sec-0073"> <h5 class="title">Subgroup analysis and investigation of heterogeneity</h5> <p>Whilst there was no significant heterogeneity in the main analysis, we followed our plan to perform subgroup analyses to estimate treatment effects for specific subgroups of participants (i.e. surgical margin status, status of regional lymph node, location of the tumour, and type of chemotherapy regimen). </p> <p>We could perform all but one of the five prespecified subgroup analyses, that is trials at low risk of bias compared to trials at high risk of bias. There was no statistical difference between postoperative adjuvant chemotherapy and no postoperative adjuvant chemotherapy in any of the subgroups, that is surgical margin status, status of regional lymph node, location of the tumour, and type of chemotherapy regimen, regarding all‐cause mortality (<a href="./references#CD012814-fig-0006" title="">Analysis 1.2</a>, <a href="./references#CD012814-fig-0007" title="">Analysis 1.3</a>, <a href="./references#CD012814-fig-0008" title="">Analysis 1.4</a>, <a href="./references#CD012814-fig-0009" title="">Analysis 1.5</a>). These findings suggest that surgical margin status, status of regional lymph node, location of the tumour, and types of chemotherapy regimen did not modify effects of postoperative adjuvant chemotherapy in comparison to no postoperative adjuvant chemotherapy. </p> </section> <section id="CD012814-sec-0074"> <h5 class="title">Sensitivity analysis</h5> <p>We performed sensitivity analyses using worst‐case and best‐case scenarios, as described in the protocol. Three trials had no losses to follow‐up (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>; <a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>). The fourth trial in this comparison had only one loss to follow‐up in each study arm (<a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>). The results did not change, mainly because the number of loss to follow‐up was very small. We do not present these two analyses. </p> <p>We also performed the sensitivity analyses using the fixed‐effect model. The results were not different, and we, therefore, reported only the results of the random‐effects model. </p> <p>We performed TSA for one dichotomous outcome, all‐cause mortality at five years (<a href="#CD012814-fig-0004">Figure 4</a>). As only 25% of the required information size was accrued, we downgraded imprecision by two levels with TSA unlike our assessment of imprecsion by one level with GRADE. We did not perform TSA for continuous outcomes as no trials provided continuous data. </p> </section> <section id="CD012814-sec-0075"> <h5 class="title">Certainty of the evidence</h5> <p>Our assessment of the certainty of the evidence for the comparison 'Adjuvant chemotherapy versus no adjuvant chemotherapy' is presented in <a href="./full#CD012814-tbl-0001">summary of findings Table 1</a>. We judged the overall certainty of the evidence for all‐cause mortality as very low (downgraded three levels) because of methodological limitations (two levels): most trials had a high risk of performance and detection bias; and imprecision (one level): the optimal information size (OIS) was not reached. We judged the overall certainty of the evidence for serious adverse events as very low (downgraded three levels) because of methodological limitations (two levels): the single trial was at high risk of performance bias and detection bias; and imprecision (one level): the OIS size was not reached (based on OIS using a conventional sample size calculation for a single trial). </p> <p>We did not downgrade for indirectness, inconsistency of evidence, or publication bias because we only included participants with cholangiocarcinoma; there was no substantial heterogeneity; and there were fewer than 10 included trials, respectively. </p> </section> </section> <section id="CD012814-sec-0076"> <h4 class="title">Adjuvant S‐1 versus gemcitabine</h4> <p>One trial, conducted in Japan, compared postoperative adjuvant S‐1 versus gemcitabine (<a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>). However, this trial included participants with intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma, and gallbladder carcinoma, and analysed the results together. We contacted the author on 22 May 2020 and 5 June 2020 to obtain specific data for participants with cholangiocarcinoma, but did not receive a response. Nevertheless, since 64 out of 70 participants in this trial had cholangiocarcinoma, we decided to analyse all trial data as provided, keeping in mind the indirectness of the evidence. </p> <section id="CD012814-sec-0077"> <h5 class="title">Primary outcomes</h5> <section id="CD012814-sec-0078"> <h6 class="title">All‐cause mortality</h6> <p>The trial by Kobayashi and colleagues reported one‐ and two‐year survival rates, with the number of participants alive, without specifying details on the participant disease initially (<a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>). We converted these data into numbers of people who died to obtain all‐cause mortality at five years. At one year, adjuvant S‐1 showed a reduction in all‐cause mortality compared with adjuvant gemcitabine, but the evidence is very uncertain (RR 0.38, 95% CI 0.15 to 0.96; 1 trial, 70 participants, <a href="./references#CD012814-fig-0011" title="">Analysis 2.1</a>, very low‐certainty evidence). At two years, adjuvant S‐1 may have little to no effect on all‐cause mortality compared with adjuvant gemcitabine, but the evidence is very uncertain (RR 0.81, 95% CI 0.58 to 1.13; 1 trial, 70 participants, <a href="./references#CD012814-fig-0012" title="">Analysis 2.2</a>, very low‐certainty evidence). </p> </section> <section id="CD012814-sec-0079"> <h6 class="title">Serious adverse events</h6> <p>The <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a> trial reported that no participants suffered serious adverse events (very low‐certainty evidence). </p> </section> <section id="CD012814-sec-0080"> <h6 class="title">Health‐related quality of life</h6> <p><a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a> did not plan to assess this outcome. </p> </section> </section> <section id="CD012814-sec-0081"> <h5 class="title">Secondary outcomes</h5> <section id="CD012814-sec-0082"> <h6 class="title">Cancer‐related mortality (death from cancer)</h6> <p><a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a> did not plan to assess this outcome. </p> </section> <section id="CD012814-sec-0083"> <h6 class="title">Time to recurrence of the tumour</h6> <p><a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a> did not plan to assess this outcome. </p> </section> <section id="CD012814-sec-0084"> <h6 class="title">Non‐serious adverse events</h6> <p><a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a> reported that the S‐1 group was associated with higher rates of biliary infection (18.1% versus 8.5%). </p> </section> </section> <section id="CD012814-sec-0085"> <h5 class="title">Certainty of the evidence</h5> <p>Our assessment of the certainty of the evidence for the comparison 'Adjuvant S‐1 versus gemcitabine' is presented in <a href="./full#CD012814-tbl-0002">summary of findings Table 2</a>. We judged the overall certainty of the evidence for all‐cause mortality and serious adverse events as very low (downgraded three levels) because of methodological limitations (one level): the trial had a high risk of performance and detection bias; indirectness (one level): participants included people with other types of cancer; and imprecision (two levels): low number of events and a wide confidence interval. In addition, the sample size was not met. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012814-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012814-sec-0086"></div> <section id="CD012814-sec-0087"> <h3 class="title" id="CD012814-sec-0087">Summary of main results</h3> <p>Four randomised clinical trials involving a total of 867 participants with cholangiocarcinoma compared postoperative adjuvant chemotherapy versus no postoperative adjuvant chemotherapy. Only one trial focused on participants with cholangiocarcinoma, whereas the other three trials also included participants with other biliary tract cancers. However, it was possible to extract data on the participants with cholangiocarcinoma from three of the trials, and we obtained the required data for the remaining trial through contact with the study authors. There was little to no difference in all‐cause mortality between postoperative adjuvant chemotherapy versus no postoperative adjuvant chemotherapy; however, we are very uncertain on the result due to the very low certainty of the evidence. We are also very uncertain as to whether postoperative adjuvant chemotherapy is associated with more serious adverse events compared with no postoperative adjuvant chemotherapy, also due to very low‐certainty evidence. The increased occurrence of adverse events in the chemotherapy group makes pharmacological sense and seems likely. Moreover, the adverse event is more likely to be worse than observed. We identified no trials assessing postoperative chemotherapy versus placebo. </p> <p>Subgroup analyses of location of the tumour, surgical margin status, status of regional lymph node, and types of chemotherapy regimen did not seem to modify the effects of postoperative adjuvant chemotherapy in comparison to no postoperative adjuvant chemotherapy. However, due to the limited data available in the included studies, the subgroup analyses do not permit any meaningful interpretation. </p> <p>In the comparison between different chemotherapy regimens, one randomised clinical trial assessed the efficacy and feasibility of postoperative adjuvant S‐1 chemotherapy versus gemcitabine after major hepatectomy for bile tract cancer, including 64 cholangiocarcinoma and 6 gallbladder carcinoma participants. Unfortunately, this trial did not report data specifically for cholangiocarcinoma participants only. At one year, adjuvant S‐1 may reduce all‐cause mortality compared with adjuvant gemcitabine. At two years, adjuvant S‐1 may have little to no effect on all‐cause mortality compared with adjuvant gemcitabine, but the evidence for this outcome is very uncertain. </p> <p>We await the results of six identified ongoing randomised clinical trials to provide more data for these comparisons. </p> </section> <section id="CD012814-sec-0088"> <h3 class="title" id="CD012814-sec-0088">Overall completeness and applicability of evidence</h3> <p>Given that we included five trials with a relatively small number of participants with cholangiocarcinoma, at overall high risk of bias, our confidence in the effect estimation of the intervention is very low. Only one trial included participants with cholangiocarcinoma alone (<a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>). The other four included trials involved participants with cholangiocarcinoma and gallbladder carcinoma; however, we obtained information for participants with cholangiocarcinoma alone from three of these trials (<a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>; <a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>). </p> <p>The included trials evaluated the effectiveness and adverse events of the two most important chemotherapy regimens for cholangiocarcinoma. One trial evaluated S‐1 chemotherapy, which is quite unique for Japan. Unfortunately, data on outcomes for participants with cholangiocarcinoma were not available. Moreover, the distribution of the countries in which the trials were conducted was limited: three trials were conducted in Japan (<a href="./references#CD012814-bbs2-0005" title="TakadaT , AmanoH , YasudaH , NimuraY , MatsushiroT , KatoH , et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer2002;95(8):1685-95. [PMID: 12365016]">Takada 2002</a>; <a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a>; <a href="./references#CD012814-bbs2-0003" title="KobayashiS , NaganoH , TomokuniA , GotohK , SakaiD , HatanoE , et al. A prospective, randomized phase ii study of adjuvant gemcitabine versus s-1 after major hepatectomy for biliary tract cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery2019;270(2):230-7. [PMID: 30339627]">Kobayashi 2019</a>), and two trials in Europe (<a href="./references#CD012814-bbs2-0002" title="EdelineJ , BenabdelghaniM , BertautA , WateletJ , HammelP , JolyJP , et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology2019;37(8):658-67. [PMID: 30707660]">Edeline 2019</a>; <a href="./references#CD012814-bbs2-0004" title="PrimroseJN , FoxRP , PalmerDH , MalikHZ , PrasadR , MirzaD , et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology2019;20(5):663-73. ">Primrose 2019</a>), which may raise the suspicion of publication bias and applicability of the evidence in general. </p> </section> <section id="CD012814-sec-0089"> <h3 class="title" id="CD012814-sec-0089">Quality of the evidence</h3> <p>We judged the overall risk of bias of the included trials as high due to lack of blinding in all five included trials. We assessed the overall certainty of the evidence using the GRADE approach (<a href="./references#CD012814-bbs2-0028" title="BalshemH , HelfandM , SchunemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6. [PMID: 21208779]">Balshem 2011</a>; <a href="./references#CD012814-bbs2-0043" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed March 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). For assessment of the outcome of interest, we judged the overall certainty of the evidence for all‐cause mortality as very low (downgraded three levels) due to methodological limitations (two levels): most trials had a high risk of performance and detection bias; and imprecision (one level): the OIS was not reached (the OIS determined using TSA). We also judged the overall certainty of the evidence for serious adverse events as very low (downgraded three levels) due to methodological limitations (two levels): the single trial had a high risk of performance and detection bias; and imprecision (one level): the OIS was not reached (the OIS determined using a conventional sample size calculation; the control group risk of 0.009, relative risk reduction (RRR) of 20%, α of 0.05, β of 0.20 (80% power), a minimum sample size was 38,926 participants in each arm). </p> </section> <section id="CD012814-sec-0090"> <h3 class="title" id="CD012814-sec-0090">Potential biases in the review process</h3> <p>We performed an extensive search of the databases. We searched for randomised clinical trials including participants with curative‐intent resection of cholangiocarcinoma who had received postoperative adjuvant chemotherapy versus no postoperative adjuvant chemotherapy. The search strategies were very broad. However, amongst the 334 references retrieved, only five publications were of interest, describing five randomised clinical trials. The paucity of trials of interest to our review may be due to the rarity of cholangiocarcinoma. Amongst our included trials, only <a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a> focused on participants with cholangiocarcinoma. The remaining trials included participants with other kinds of bile duct cancers, resulting in heterogeneity amongst the trials. The lack of reporting of adverse events of the intervention in the included trials is another potential bias in the review process. We did not find any relevant observational studies reporting on harms in our search for randomised trials. By focusing mainly on randomised trials, we are aware that the review result regarding the potential harms of the intervention may be biased towards assessments of benefits. We were unable to construct funnel plots due to the limited number of trials, which means that we may unwittingly have perpetuated a publication bias. </p> <p>None of the review authors has any links to drug companies or a financial interest in the prescription of the chemotherapeutic agents assessed in this review, nor were they involved in the conduct of any included trial, thus there were no issues associated to bias secondary to conflicts of interests in this review. </p> </section> <section id="CD012814-sec-0091"> <h3 class="title" id="CD012814-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>Six systematic reviews evaluating the benefits of postoperative adjuvant therapy for biliary tract cancer have been published (<a href="./references#CD012814-bbs2-0059" title="HorganAM , AmirE , WalterT , KnoxJJ . Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology2012;30(16):1934-40. [PMID: 22529261]">Horgan 2012</a>; <a href="./references#CD012814-bbs2-0112" title="ZhuGQ , ShiKQ , YouJ , ZouH , LinYQ , WangLR , et al. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Alimentary Pharmacology &amp; Therapeutics2014;40(7):759-70. [PMID: 25099956]">Zhu 2014</a>; <a href="./references#CD012814-bbs2-0041" title="GhidiniM , TomaselloG , BotticelliA , BarniS , ZabbialiniG , SeghezziS , et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB: the Official Journal of the International Hepato-Pancreato-Biliary Association2017;19(9):741-8. [PMID: 28684194]">Ghidini 2017</a>; <a href="./references#CD012814-bbs2-0071" title="MaKW , CheungTT , LeungB , SheBW , ChokKS , ChanAC , et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis. Medicine2019;98(5):e14013. [PMID: 30702559]">Ma 2019</a>; <a href="./references#CD012814-bbs2-0104" title="WangML , KeZY , YinS , LiuCH , HuangQ . The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: a meta-analysis and systematic review. Hepatobiliary &amp; Pancreatic Diseases International2019;18(2):110-6. [PMID: 30470543]">Wang 2019</a>; <a href="./references#CD012814-bbs2-0087" title="RangarajanK , SimmonsG , ManasD , MalikH , HamadyZZ . Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis. European Journal of Surgical Oncology2020;46(4 Pt A):684-93. [PMID: 31761507]">Rangarajan 2020</a>). None of these reviews assessed the adverse effects of adjuvant chemotherapy. <a href="./references#CD012814-bbs2-0059" title="HorganAM , AmirE , WalterT , KnoxJJ . Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology2012;30(16):1934-40. [PMID: 22529261]">Horgan 2012</a> included 20 studies involving 6712 participants, but the majority of the studies were observational studies, and the studies included all types of bile duct cancer. The adjuvant therapy of interest in this meta‐analysis included adjuvant chemotherapy and adjuvant chemo‐radiation. <a href="./references#CD012814-bbs2-0059" title="HorganAM , AmirE , WalterT , KnoxJJ . Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology2012;30(16):1934-40. [PMID: 22529261]">Horgan 2012</a> recommended adjuvant therapy for bile duct cancer, especially for those with lymph node‐positive disease and R1 (microscopically not free surgical margin) disease. <a href="./references#CD012814-bbs2-0112" title="ZhuGQ , ShiKQ , YouJ , ZouH , LinYQ , WangLR , et al. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Alimentary Pharmacology &amp; Therapeutics2014;40(7):759-70. [PMID: 25099956]">Zhu 2014</a> included 12 studies involving 1361 participants with all types of bile duct cancer and assessed the benefits of various adjuvant modalities. This review claimed that adjuvant chemotherapy with gemcitabine increased survival. <a href="./references#CD012814-bbs2-0041" title="GhidiniM , TomaselloG , BotticelliA , BarniS , ZabbialiniG , SeghezziS , et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB: the Official Journal of the International Hepato-Pancreato-Biliary Association2017;19(9):741-8. [PMID: 28684194]">Ghidini 2017</a> included 30 studies involving a total of 22,499 participants with cholangiocarcinoma and gallbladder carcinoma. The intervention of interest was adjuvant chemotherapy, but the majority of the included studies were observational studies. The authors of this review claimed that adjuvant chemotherapy administration led to an overall survival benefit in resected bile duct tumour. <a href="./references#CD012814-bbs2-0071" title="MaKW , CheungTT , LeungB , SheBW , ChokKS , ChanAC , et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis. Medicine2019;98(5):e14013. [PMID: 30702559]">Ma 2019</a> included 15 retrospective cohort studies involving 5060 participants with resectable intrahepatic cholangiocarcinoma. The intervention of interest was adjuvant chemotherapy, but all of the studies included in this review were retrospective cohort studies. <a href="./references#CD012814-bbs2-0071" title="MaKW , CheungTT , LeungB , SheBW , ChokKS , ChanAC , et al. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: a meta-analysis. Medicine2019;98(5):e14013. [PMID: 30702559]">Ma 2019</a> concluded that adjuvant chemotherapy is associated with improved overall survival and should be considered in patients with intrahepatic cholangiocarcinoma following curative resection, and in particular in those with advanced disease. <a href="./references#CD012814-bbs2-0104" title="WangML , KeZY , YinS , LiuCH , HuangQ . The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: a meta-analysis and systematic review. Hepatobiliary &amp; Pancreatic Diseases International2019;18(2):110-6. [PMID: 30470543]">Wang 2019</a> included 19 studies involving 11,458 participants with cholangiocarcinoma. The intervention of interest was adjuvant chemotherapy. One included study was a randomised clinical trial, whilst the other 18 included studies were retrospective observational studies. <a href="./references#CD012814-bbs2-0104" title="WangML , KeZY , YinS , LiuCH , HuangQ . The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: a meta-analysis and systematic review. Hepatobiliary &amp; Pancreatic Diseases International2019;18(2):110-6. [PMID: 30470543]">Wang 2019</a> concluded that postoperative adjuvant chemotherapy improves overall survival in intrahepatic and hilar cholangiocarcinoma patients, but that distal cholangiocarcinoma gained no benefit from adjuvant chemotherapy. <a href="./references#CD012814-bbs2-0087" title="RangarajanK , SimmonsG , ManasD , MalikH , HamadyZZ . Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis. European Journal of Surgical Oncology2020;46(4 Pt A):684-93. [PMID: 31761507]">Rangarajan 2020</a> included 35 studies involving 42,917 participants with cholangiocarcinoma and gallbladder carcinoma. The intervention of interest was adjuvant chemotherapy. The review included five randomised trials and 30 retrospective cohort studies and advocated the use of adjuvant therapy in bile duct cancer after curative‐intent resection. </p> <p>All of the aforementioned reviews included both randomised clinical trials and observational studies. Four reviews recruited participants with all types of bile duct cancer (cholangiocarcinoma and gallbladder carcinoma) (<a href="./references#CD012814-bbs2-0059" title="HorganAM , AmirE , WalterT , KnoxJJ . Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology2012;30(16):1934-40. [PMID: 22529261]">Horgan 2012</a>; <a href="./references#CD012814-bbs2-0112" title="ZhuGQ , ShiKQ , YouJ , ZouH , LinYQ , WangLR , et al. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Alimentary Pharmacology &amp; Therapeutics2014;40(7):759-70. [PMID: 25099956]">Zhu 2014</a>; <a href="./references#CD012814-bbs2-0041" title="GhidiniM , TomaselloG , BotticelliA , BarniS , ZabbialiniG , SeghezziS , et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB: the Official Journal of the International Hepato-Pancreato-Biliary Association2017;19(9):741-8. [PMID: 28684194]">Ghidini 2017</a>; <a href="./references#CD012814-bbs2-0087" title="RangarajanK , SimmonsG , ManasD , MalikH , HamadyZZ . Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis. European Journal of Surgical Oncology2020;46(4 Pt A):684-93. [PMID: 31761507]">Rangarajan 2020</a>). Three reviews included both adjuvant chemotherapy and adjuvant chemo‐radiation (<a href="./references#CD012814-bbs2-0059" title="HorganAM , AmirE , WalterT , KnoxJJ . Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. Journal of Clinical Oncology2012;30(16):1934-40. [PMID: 22529261]">Horgan 2012</a>; <a href="./references#CD012814-bbs2-0112" title="ZhuGQ , ShiKQ , YouJ , ZouH , LinYQ , WangLR , et al. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Alimentary Pharmacology &amp; Therapeutics2014;40(7):759-70. [PMID: 25099956]">Zhu 2014</a>; <a href="./references#CD012814-bbs2-0041" title="GhidiniM , TomaselloG , BotticelliA , BarniS , ZabbialiniG , SeghezziS , et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB: the Official Journal of the International Hepato-Pancreato-Biliary Association2017;19(9):741-8. [PMID: 28684194]">Ghidini 2017</a>). </p> <p>Our review includes only randomised clinical trials aimed to assess the benefits and harms of adjuvant chemotherapy for participants with cholangiocarcinoma after curative‐intent resection. We found insufficient evidence to support or refute the use of adjuvant chemotherapy for this condition. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012814-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. Date of search 28 April 2021." data-id="CD012814-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. Date of search 28 April 2021.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012814-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012814-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Trial Sequential Analysis (TSA) on all‐cause mortality Four trials provided data on all‐cause mortality. The diversity‐adjusted required information size (DARIS) was calculated based on event proportion in the control group of 59.3% (255/430), relative risk reduction (RRR) of 10%, type I error of 2.5%, type II error of 10% (90% power), and heterogeneity correction based on model variance (trial diversity was 0%). The required information size was 3473 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward‐sloping lines), or futility (red outward lines). The accrued number of randomised participants is only 25% of the DARIS. The green dashed lines show conventional boundaries (2.5%). The TSA‐adjusted risk ratio was 0.92 (TSA‐adjusted confidence interval 0.74 to 1.16); two‐sided hypothesis testing, O’Brien‐Fleming α‐spending function." data-id="CD012814-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p><b>Trial Sequential Analysis (TSA) on all‐cause mortality</b> </p> <p>Four trials provided data on all‐cause mortality. The diversity‐adjusted required information size (DARIS) was calculated based on event proportion in the control group of 59.3% (255/430), relative risk reduction (RRR) of 10%, type I error of 2.5%, type II error of 10% (90% power), and heterogeneity correction based on model variance (trial diversity was 0%). The required information size was 3473 participants. The cumulative Z‐curve (blue line) did not cross the trial sequential monitoring boundaries for benefit or harm (red inward‐sloping lines), or futility (red outward lines). The accrued number of randomised participants is only 25% of the DARIS. The green dashed lines show conventional boundaries (2.5%). The TSA‐adjusted risk ratio was 0.92 (TSA‐adjusted confidence interval 0.74 to 1.16); two‐sided hypothesis testing, O’Brien‐Fleming α‐spending function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 1: All‐cause mortality" data-id="CD012814-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 1: All‐cause mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 2: All‐cause mortality (margin status). Subgroup analysis" data-id="CD012814-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 2: All‐cause mortality (margin status). Subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 3: All‐cause mortality (lymph node status). Subgroup analysis" data-id="CD012814-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 3: All‐cause mortality (lymph node status). Subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 4: All‐cause mortality (location of tumour). Subgroup analysis" data-id="CD012814-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 4: All‐cause mortality (location of tumour). Subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 5: All‐cause mortality (chemotherapy regimen). Subgroup analysis" data-id="CD012814-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 5: All‐cause mortality (chemotherapy regimen). Subgroup analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 6: Serious adverse events" data-id="CD012814-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Adjuvant chemotherapy versus no chemotherapy, Outcome 6: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adjuvant S‐1 versus gemcitabine, Outcome 1: All‐cause mortality: 1 year" data-id="CD012814-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Adjuvant S‐1 versus gemcitabine, Outcome 1: All‐cause mortality: 1 year</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012814-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/urn:x-wiley:14651858:media:CD012814:CD012814-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Adjuvant S‐1 versus gemcitabine, Outcome 2: All‐cause mortality: 2 years" data-id="CD012814-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_t/tCD012814-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Adjuvant S‐1 versus gemcitabine, Outcome 2: All‐cause mortality: 2 years</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/media/CDSR/CD012814/image_n/nCD012814-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012814-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Adjuvant chemotherapy compared with no chemotherapy for resectable cholangiocarcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adjuvant chemotherapy compared with no chemotherapy for resectable cholangiocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with resectable cholangiocarcinoma<br/><b>Setting:</b> secondary care <br/><b>Intervention:</b> adjuvant chemotherapy<br/><b>Comparison:</b> no chemotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no chemotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with adjuvant chemotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality at 5 years</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.92<br/>(0.84 to 1.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>867<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We used Trial Sequential Analysis to calculate diversity‐adjusted required information size (DARIS). DARIS was calculated based on event proportion in the control group of 59.3% (255/430), risk ratio of 10%, type I error of 2.5%, type II error of 10% (90% power), and heterogeneity correction based on model variance (trial diversity was 0%). The required information size was 3473 participants. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>593 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>546 per 1000<br/>(498 to 599) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> <p>Follow‐up:</p> <p>median: 79.4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 17.82<br/>(2.43 to 130.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>219<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events in the trial report were described as any serious adverse event, and not a specific toxicity. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>168 per 1000<br/>(23 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>There was no difference in time to definitive deterioration of global health‐related quality of life between those who received postoperative adjuvant GEMOX (gemcitabine and oxaliplatin) and those who did not. </p> <p>Participants receiving postoperative adjuvant capecitabine had worse social functioning compared with those who did not receive adjuvant chemotherapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both trials reported overall outcomes for all participants (cholangiocarcinoma and gallbladder carcinoma). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer‐related mortality</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials reported this outcome for participants with cholangiocarcinoma alone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TIme to recurrence of the tumour</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials reported this outcome for participants with cholangiocarcinoma alone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included trials reported this outcome for participants with cholangiocarcinoma alone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to methodological limitations (two levels): most trials had a high risk of performance and detection bias; and imprecision (one level); the optimal information size (OIS) of 3473 participants was not reached (see comment).<br/><sup>2</sup>Downgraded due to methodological limitations (two levels): the trial had a high risk of performance and detection bias; and imprecision (one level); the optimal information size (OIS) was not met (based on OIS using a conventional sample size calculation, the control group risk of 0.009, relative risk reduction (RRR) of 20%, α of 0.05, β of 0.20, the required sample size was 38,926 participants in each trial group). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Adjuvant chemotherapy compared with no chemotherapy for resectable cholangiocarcinoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012814-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Adjuvant S‐1 compared to gemcitabine for resectable cholangiocarcinoma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Adjuvant S‐1 compared to gemcitabine for resectable cholangiocarcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with resectable cholangiocarcinoma <br/><b>Setting:</b> secondary care <br/><b>Intervention:</b> adjuvant S‐1<br/><b>Comparison:</b> adjuvant gemcitabine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with adjuvant gemcitabine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with adjuvant S‐1</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality: 1‐year overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.38<br/>(0.15 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝ <br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64 of 70 participants in this trial had cholangiocarcinoma; 6 participants had gallbladder carcinoma. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000<br/>(56 to 357) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality: 2‐year overall survival</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/>(0.58 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝ <br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64 of 70 participants in this trial had cholangiocarcinoma; 6 participants had gallbladder carcinoma. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>743 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>602 per 1000<br/>(431 to 839) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>70<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝ <br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64 of 70 participants in this trial had cholangiocarcinoma; 6 participants had gallbladder carcinoma. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT</b> : randomised clinical trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded due to methodological limitations (one level): the trial had a high risk of performance and detection bias; indirectness (one level): participants included people with other types of cancer; and imprecision (two levels): the sample size was not met, and there was a low number of events and a wide confidence interval. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Adjuvant S‐1 compared to gemcitabine for resectable cholangiocarcinoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012814-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Grade 3/4 haematologic adverse events</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants<br/>with an event</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Proportion (%)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leucocytes</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant gemcitabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neutrophils</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adjuvant gemcitabine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012814-bbs2-0001" title="EbataT , HiranoS , KonishiM , UesakaK , TsuchiyaY , OhtsukaM , et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. British Journal of Surgery2018;105(3):192-202. [PMID: 29405274]">Ebata 2018</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58.4</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Grade 3/4 haematologic adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/full#CD012814-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012814-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adjuvant chemotherapy versus no chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 All‐cause mortality (margin status). Subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.86, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Surgical margin positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.88, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Surgical margin negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 All‐cause mortality (lymph node status). Subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.66, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Lymph node positive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.89, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Lymph node negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.51, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 All‐cause mortality (location of tumour). Subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.83, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Intrahepatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Extrahepatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All‐cause mortality (chemotherapy regimen). Subgroup analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Gemcitabine‐based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 5‐FU‐based chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Adjuvant chemotherapy versus no chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012814-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adjuvant S‐1 versus gemcitabine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality: 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 All‐cause mortality: 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Adjuvant S‐1 versus gemcitabine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012814.pub2/references#CD012814-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012814.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012814-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012814-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012814-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012814-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012814-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD012814-note-0007">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012814-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012814-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012814\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012814\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012814\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012814\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012814\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=nnwvukoo&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012814.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012814.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012814.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012814.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012814.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728493496"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012814.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728493499"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012814.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec5d69c299367',t:'MTc0MDcyODQ5My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 